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Assay window: The difference in signal of positive and negative controls. 
Negative control or control 1: A negative control in a screening assay is the control that 
shows response as expected from an inactive compound in the assay. 
Pan-DUB inhibitor: An inhibitor that specifically inhibits the activity of DUBs but not other 
enzymes. 
Positive control or control 2: A positive control in a screening assay is the control that 
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reaction which can be obtained by removing the enzyme or by treatment with a known 
inhibitor. 
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number Tb927.11.1930. 
 
 
Summary 
 
Millions of people suffer from and more than 1 billion people live at the risk of 
contracting human African trypanosomiasis (HAT), Chagas disease and 
leishmaniasis. These diseases are caused by Trypanosoma brucei, T. cruzi and 
Leishmania spp. respectively - members of the class Kinetoplastida. The current 
treatments against these diseases are old and have complex administration 
profiles, low efficacy and/or serious side effects. The causative parasites are also 
developing resistance against the available treatments. Therefore, there is an 
urgent need to discover new treatments for these diseases. For this it is important 
to focus on new targets that have proven to be tractable. The ubiquitin machinery 
provides an exciting opportunity as the target for development of new therapies. 
Deubiquitinases are the enzymes responsible for removing ubiquitin from target 
proteins and regulate a whole lot of cellular processes. They are being pursued as 
targets in several therapeutic areas. It was shown that some deubiquitinases are 
essential in T. brucei. The three parasites have similar genomic sequence and 
biology (El-Sayed et al., 2005). Thus compounds targeting a conserved target 
could be active against all three parasites (Khare et al., 2016). 
 
We focussed our efforts on the discovery of new and selective small molecules 
capable of killing the parasite by ablating the activity of an essential deubiquitinase 
in T. brucei. For this we expressed and purified the enzyme and screened the GSK 
library of ~1.7 million compounds. After confirming the hits and determining their 
potencies, we followed a systematic triage strategy to finally obtain 64 hits with the 
IC50 in biochemical assay between 3 to 50 µM. These hits were tested for their 
potencies against whole cell T. brucei, T. cruzi and L. donovani and for their 
cytotoxic effect on HepG2 cells. Finally, we were able to identify 14 selective hits 
that showed activity against whole cell T. brucei and were either not cytotoxic or 
the IC50 was at least 2.5 times higher against T. brucei compared to HepG2 cells. 
Also, we were able to identify 2 hits that showed IC50 of 8.7 µM and 6.6 µM against 
T. brucei, 3.98 µM and 1.99 µM against L. donovani, 15 µM and 10.4 µM against T. 
cruzi respectively. These compounds provide very promising starting points for 
medicinal chemistry efforts. 
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Resumen 
 
Millones de personas sufren y más de 1000 millones están en riesgo de contraer la 
tripanosomiasis Africana, el mal de Chagas o la leishmaniasis. Estas 
enfermedades son causadas por los kinetoplástidos Trypanosoma brucei, T. cruzi 
y Leishmania spp., respectivamente. Los tratamientos actualmente disponibles 
para estas enfermedades son viejos y poseen perfiles complejos de 
administración, baja eficacia y/o serios efectos adversos. Además, los parásitos 
causantes están desarrollando resistencias a los tratamientos existentes. Por 
estas razones hay una necesidad urgente de descubrir nuevos tratamientos para 
estas dolencias. Es por tanto importante enfocarse en nuevas dianas que 
demuestren ser tratables. La maquinaria de ubiquitina ofrece una oportunidad 
excitante como diana para el desarrollo de nuevas terapias. Las desubiquitinasas 
son enzimas responsables de retirar moléculas de ubiquitina de proteínas diana y 
regulan numerosos procesos celulares. Estas enzimas ya están siendo exploradas 
como dianas en otras áreas terapéuticas. Recientemente se ha demostrado que 
algunas desubiquitinasas son esenciales en T. brucei. Los 3 parásitos tienen 
genomas y biologías similares (El-Sayed et al., 2005). Así, cabe esperar que las 
moléculas que modulen una diana conservada sean activas frente a los 3 
patógenos (Khare et al., 2016). 
 
Hemos enfocado nuestros esfuerzos en el descubrimiento de compuestos de bajo 
peso molecular que sean novedosos y capaces de matar selectivamente al 
parásito mediante la anulación de la actividad de una desubiquitinasa esencial de 
T. brucei. Para ello hemos expresado y purificado la enzima y hemos llevado a 
cabo una campaña de bioprospección molecular a gran escala usando la 
colección de 1.7 millones de compuestos de GSK. Tras confirmar los activos 
iniciales y determinar sus potencias inhibitorias, seguimos una estrategia de 
perfilado biológico sistemática hasta obtener la selección final de 64 compuestos 
con potencias en el ensayo bioquímico comprendidas entre 3 y 50 µM. 
Procedimos entonces a probar las actividades tripanocidas de estos compuestos 
enfrentándolos a T. brucei, T. cruzi y L. donovani y también estudiamos sus 
efectos citotóxicos sobre células HepG2. Finalmente, fuimos capaces de identificar 
14 moléculas selectivas que además mostraban actividad en ensayos con célula 
entera de T. brucei y mostraban una citotoxicidad inapreciable o de una magnitud 
al menos 2.5 veces inferior que frente a T. brucei en comparación con células 
HepG2. Cabe destacar que hemos sido capaces de identificar 2 compuestos pan-
kinetocidas que mostraron valores de IC50 de 8.7 µM y 6.6 µM frente a T. brucei, 
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3.98 µM y 1.99 µM frente a L. donovani, 15 µM y 10.4 µM frente a T. cruzi, 
respectivamente. Estas estructuras químicas suponen puntos de partida muy 
prometedores para esfuerzos de química médica que conduzcan a su desarrollo. 
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1.1 The parasite burden 
 
This work is an attempt to identify novel starting points for developing new 
treatments against human African trypanosomiasis (HAT), Chagas disease and 
leishmaniasis. These diseases are caused by Trypanosoma brucei, Trypanosoma 
cruzi and Leishmania spp. respectively, all three of which are dixenous i.e. have 
two hosts in their life cycle. These organisms are classified in the family 
Trypanosomatidae, of the class Kinetoplastida, phylum Euglenozoa, super group 
Excavata of the domain Eukaryota. The Kinetoplastida have a defining 
characteristic which is the kinetoplast, an unusually structured DNA granule inside 
the mitochondria. All the members of Trypanosomatidae are obligate parasites.  
 
HAT or sleeping sickness is caused in humans by two subspecies of T. brucei- 
T. b. gambiense and T. b. rhodesiense. Most cases of sleeping sickness are 
caused by T. b. gambiense. The disease is largely prevalent in the sub-Saharan 
Africa. Every year ~10,000 new cases of HAT are reported, around 50-60,000 
people suffer from the disease and 70 million people are at the risk of contracting it 
(WHO, CDC). Both subspecies of T. brucei are transmitted by the tsetse fly (genus 
Glossina). An infected tsetse fly injects metacyclic trypanomastigotes in humans 
when it takes a blood meal. Once in humans they transform into bloodstream form. 
In stage I of the disease the parasite stays in the peripheral circulation- for example 
in blood and lymph and multiplies by binary fission. Typical symptoms during stage 
I infection include swollen lymph nodes, fever, headache and muscle and joint 
ache. After 1-2 years in the case of T. b. gambiense and after only a few weeks in 
the case of T. b. rhodesiense, the parasite enters the central nervous system and 
causes severe neurological disorders. This is the stage II of the disease. If left 
untreated, infection from either subspecies will prove fatal.  
  
Chagas disease or American trypanosomiasis is caused by Trypanosoma cruzi. 
The disease is widespread in Central and South America. The number of people 
suffering from Chagas disease is approximated to be around 7 to 8 million, with 
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50,000 new cases each year. The number of people living at the risk of contracting 
Chagas disease is around 120 million (WHO, CDC). T. cruzi is transmitted by the 
triatomine bug (genus Triatoma). When an infected triatomine bug takes a blood 
meal it passes T. cruzi metacyclic trypanomastigotes in the faeces. These 
trypanomastigotes enter the host through the wound or through mucosal 
membranes. Once in the host, the trypanomastigotes differentiate into intracellular 
amastigotes. The amastigotes will multiply by binary fission and transform into 
trypanomastigotes that are released in the bloodstream and can infect more cells 
and the cycle will continue. Chagas disease has 2 phases: acute and chronic. 
Acute phase is mild or asymptomatic. The symptoms could include fever, 
headache, swollen lymph nodes and swelling at the site of infection. Post acute 
phase an infected person can stay asymptomatic for years and might not even 
progress to chronic phase. In chronic phase the patients suffer from cardiac, 
digestive or neurological disorders. If left untreated, the infection can cause death 
or heart failure due to degradation of heart muscles.  
 
In humans leishmaniasis can be caused by more than 20 species of Leishmania. 
Leishmaniasis is spread in around 90 tropical and sub-tropical countries. An 
estimated 12 million people are infected with Leishmania and more than 1 million 
new cases are reported every year (Alvar et al., 2012, WHO, CDC). More than 1 
billion people live at a risk of being infected by Leishmania spp. The parasites are 
transmitted by the sandflies (genus Phlebotomus). An infected sandfly injects 
promastigotes in humans when it takes a blood meal. These promastigotes either 
actively invade or are phagocytosed into macrophages. Inside the macrophage the 
promastigotes differentiate into amastigotes. The amastigotes multiply inside the 
macrophages by binary fission and can go on to infect more cells. Depending on 
the species and environmental factor, the disease can present three main clinical 
manifestations: visceral leishmaniasis (VL) or kala-azar, cutaneous leishmaniasis 
and mucocutaneous leishmaniasis (MCL). VL affects internal organs like spleen 
and liver and is fatal if left untreated. The symptoms include fever, swollen spleen 
and liver, weight loss, anaemia, leucopoenia and thrombocytopenia. Cutaneous 
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leishmaniasis is the most common form of leishmaniasis. Cutaneous leishmaniasis 
patients develop skin lesions or sores. The lesions heal over time but can leave 
unpleasant scars and cause serious disabilities. MCL causes destruction of 
mucosal membranes of the nose, mouth or throat. 
 
These three diseases put together have a very significant prevalence and mortality. 
They pose a serious socio-economic burden which has been estimated to be tens 
of billions of dollars every year. Despite this, as will be discussed in detail in the 
next section, a look at the currently available treatments points towards an urgent 
need to discover new treatments. 
 
1.2 Available treatments: the unmet medical need 
 
Kinetoplastid diseases have been neglected for decades in terms of research and 
development into drugs. Consequently, there are only a few treatments available 
that are old and have several disadvantages like high cost, toxicity, long 
administration profiles, a difficult route of administration and/or low efficacy in 
endemic areas.  
 
For treatment of HAT, only five drugs are available. These drugs and the stages 
targeted are listed in Table 1.1. Melarsoprol is the only available treatment for 
stage II infections of T. b. rhodesiense and is also effective against stage II of T. b. 
gambiense. Suramin and pentamidine are used to treat stage I of  T. b. gambiense 
infection. Eflornithine is effective against T. b. gambiense. However all of these 
drugs either have a complex dosage regimen and/or have very serious side 
effects. NECT (nifurtimox–eflornithine combination therapy) is relatively safer, has 
shorter administration profile as compared to eflornithine and has been shown not 
to be inferior to standard eflornithine therapy (Priotto et al., 2009). More 
importantly, the parasite has started showing drug resistance in several foci 
(Barrett et al., 2011, Baker et al., 2013).  
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For the acute stage and congenital infection of Chagas disease benznidazole and 
nifurtimox are effective treatments (Bahia-Oliveira et al., 2000). However they show 
poor efficacy against the chronic stages (Cancado, 2002). The side effects of 
benznidazole treatment include bone marrow depression, anorexia, peripheral 
neuropathy and allergic dermatitis. Nifurtimox treatment can cause anorexia, 
polyneuropathy, psychic alterations and nausea amongst other effects (Castro et 
al., 2006, Wilkinson and Kelly, 2009). The dosage regimen for benznidazole and 
nifurtimox can last up to 60 and 90 days respectively. Due to the long 
administration profile the treatment is often not completed and increases the 
chances of emergence of resistance. Resistance against both these drugs has 
been reported (Wilkinson et al., 2008, Campos et al., 2014). 
  
Table 1.1: WHO list of essential medicines for human African 
trypanosomiasis. 
 
Drug Year Parasite targeted Drawbacks/Side effects 
Suramin 1920 Stage I 
T. b. rhodesiense 
IV infusion - 5 days. Nephrotoxicity, peripheral 
neurotoxicity and bone marrow toxicity, which are 
usually mild and reversible (Malvy and Chappuis, 2011). 
Pentamidine 1940 Stage I 
T. b. gambiense 
IV infusion or intramuscular injection – 10 days. Pain at 
the injection site (rarely complicated by aseptic or septic 
abscess), hypoglycemia and hypotension (Malvy and 
Chappuis, 2011).  
Melarsoprol 1949 Stage II 
T. b. gambiense, 
T. b. rhodesiense 
Arsenic-based derivative. Lengthy IV dosing schedule 
(for 3 days every 7 days- total 9 days). A poorly 
tolerated drug: encephalopathic syndrome in 5–10% 
patients with high case-fatality rate, peripheral 
neuropathy, hepatic toxicity, skin rash, acute phlebitis 
and vein sclerosis. 
Eflornithine 1990 Stage II 
T. b. gambiense  
Safer than melarsoprol. But 56 intravenous infusions, 
>30 min each over 14 days. Bone marrow suppression 
and seizures. (Balasegaram et al., 2009, Chappuis et 
al., 2005, Malvy and Chappuis, 2011) 
Nifurtimox–
eflornithine 
combination 
2009 T. b. gambiense It simplifies the use of eflornithine by reducing the 
duration of treatment and the number of IV perfusions, 
but it was not studied for T. b. rhodesiense.  
 
For the treatment of different clinical manifestations of leishmaniasis pentavalent 
antimonials, amphotericin B, paromycin and miltefosine are used. Most of these 
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treatments are old, have long dosage regimens, some have very serious side 
effects and the parasite has developed resistance against some (den Boer et al., 
2009, Nagle et al., 2014).  
 
Clearly, there is an urgent need for new drugs that are more effective, have higher 
potency and therefore require a lower dosage or shorter administration profiles, 
and have less side effects. Furthermore, it is very important that the drugs are 
inexpensive because these diseases are closely associated with poverty and are 
primarily found in areas with underdeveloped public health systems. For the 
development of new drugs with novel mechanisms of actions, it is important to dig 
deeper into the parasite cellular biology and identify new targets. 
 
1.3 Ubiquitin machinery as drug target 
 
Ubiquitin is a 76 residues long polypeptide with a molecular weight of around 
8.5 kDa. The structure of ubiquitin is shown in Figure 1.1. Ubiquitin was first 
reported as a ubiquitous immunopoietic polypeptide (UBIP) with lymphocyte-
differentiating properties (Goldstein et al., 1975). Later, Ciechanover et al. 
identified a heat-stable ATP-dependent proteolysis factor (APF-1) in reticulocytes 
(Ciehanover et al., 1978) which formed high molecular weight covalent conjugates 
with reticulocyte proteins in an ATP-dependent manner (Ciechanover et al., 1980). 
APF-1 was later identified to be ubiquitin (Wilkinson et al., 1980). Hershko et al. 
(Hershko et al., 1980) first demonstrated two distinct enzymatic activities of the 
ubiquitin system. First they showed that the APF-1 conjugation to target proteins 
was enzyme-catalysed. They called this enzyme APF-1-protein amide synthetase 
and showed that the conjugation is processive i.e. several APF-1 moieties can be 
conjugated to a single target. The second enzymatic activity demonstrated was 
that of an amidase by showing that the APF-1 was regenerated from APF-1-protein 
conjugates. Aaron Ciechanover, Avram Hershko and Irwin Rose were awarded the 
Nobel Prize in chemistry in 2004 for the discovery of ubiquitin-mediated protein 
degradation. The field continues to grow immensely. For example, a combined 
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broad literature search using Embase (Elsevier), for the terms ‘ubiquitin’ or 
‘ubiquitination’ in January 2017 yielded around 67000 records with 5000 to 6000 
papers being published each year. 
 
 
 
Figure 1.1 Structure of ubiquitin 
The representation of the structure shown above is taken from (Komander, 
2009) with the structure PDB code 1UBQ (Vijay-Kumar et al., 1987).  Ubiquitin 
has seven lysines and one methionine that act as substrates for another 
ubiquitin to attach and hence allow chain formation. 
 
Ubiquitin covalently attaches to the ε-amino group of a lysine of the target protein 
via its C-terminal glycine forming an isopeptide linkage. As we now know, 
ubiquitination is a three-step process (Figure 1.2) involving activation, conjugation 
and ligation. Ubiquitin first covalently binds to the active site cysteine of an E1 
enzyme or ubiquitin activating enzyme in an ATP-dependent manner. This ubiquitin 
is then transferred to an E2 enzyme referred to as ubiquitin conjugating enzyme. 
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The E2 then transfers the ubiquitin to an E3 ligase, which in turn transfers it to a 
lysine of the target protein, where it attaches via an isopeptide linkage. The human 
genome encodes for two E1 enzymes, 37 E2 enzymes and >600 E3 enzymes 
(Deshaies and Joazeiro, 2009, Markson et al., 2009, Michelle et al., 2009, 
Groettrup et al., 2008). Like most post-translational modifications (PTMs) 
ubiquitination is a reversible process. Enzymes that cleave ubiquitin from the target 
are called deubiquitinases (DUBs). DUBs were identified by Hershko et al. 
(Hershko et al., 1980) as amidases. These are discussed in greater detail in 
section 1.4. 
 
 
Figure 1.2 The ubiquitination pathway 
Ubiquitin activation by E1s is an ATP-dependent process. This activated 
ubiquitin is transferred to an E2, and further an E3 couples it to the target 
protein. To remove the ubiquitin, DUBs come into action (Nicholson et al., 
2014). 
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The ubiquitin code is very complex (Yau and Rape, 2016, Komander, 2009). 
Ubiquitin itself has 7 lysine residues viz. K6, K11, K27, K29, K33, K48 and K64 and 
also a terminal methionine (M1) residue which all can act as substrates for another 
ubiquitin to attach (Figure 1.1). This results in the formation of ubiquitin chains on 
a target protein. A protein can either be monoubiquitinated i.e. a single Ub on a 
single lysine, or multimonoubiquitinated i.e. a single Ub on multiple lysine residues 
or polyubiquitinated i.e. a chain of ubiquitin gets attached to a lysine residue. The 
polyubiquitin chains on a target can in turn either be homotypic or heterotypic. In 
homotypic chains all ubiquitins in the chain are attached by the same lysine or 
methionine. In a heterotypic chain the ubiquitins are attached by different lysines. 
The nature of ubiquitination on the target proteins can determine the fate of the 
target in different ways by signalling it for various roles or to different cellular 
localizations (reviewed in (Komander, 2009, Yau and Rape, 2016)). For example, 
K48 and K11-linked homotypic polyubiquitin chains target a protein primarily to the 
proteasome for degradation (Chau et al., 1989). However, a minimum tetraubiquitin 
chain is required to efficiently target a protein for proteasomal degradation 
(Thrower et al., 2000). Polyubiquitin chains of other linkage types regulate proteins 
by signalling for non-proteasomal fate. For example, K63-linked chains target 
receptors to the lysosome (Lauwers et al., 2009) and play an important role in a 
variety of cellular processes like DNA repair (Hoege et al., 2002), NF-κB activation 
(Deng et al., 2000) and mitophagy (Ordureau et al., 2015, Cunningham et al., 
2015). K6 and K11-linked chains also regulate mitophagy (Cunningham et al., 
2015). K27-linked linkages regulate DNA damage response (Gatti et al., 2015). 
Thus, the ubiquitin machinery has been shown to regulate a wide variety of cellular 
functions (Ikeda and Dikic, 2008, Haglund et al., 2003, Mukhopadhyay and 
Riezman, 2007, Hicke, 2001). The ubiquitin machinery is composed of more than 
one thousand proteins and many of them have been validated as drug targets in 
several therapeutic areas (reviewed in (Tcherpakov, 2013, Nalepa et al., 2006, 
Cohen and Tcherpakov, 2010)). These are discussed in detail in the following 
sections. 
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1.3.1 Proteasome as drug target 
 
The global research and development market for ubiquitin proteasome is expected 
to grow with a five-year compound annual growth rate of 14.2% from estimated 
USD 2.9 billion in 2013 to USD 5.5 billion by 2018 (Tcherpakov, 2013). The 
success of Bortezomib (PS-341) (Adams, 2002) and the recent approval of 
Carfilzomib (Herndon et al., 2013), both proteasome inhibitors for the treatment of 
multiple myeloma, have unequivocally established the proteasome as an attractive 
drug target (Nalepa et al., 2006, Cohen and Tcherpakov, 2010). Additionally, there 
are several proteasome inhibitors in different stages of clinical trials (Cohen and 
Tcherpakov, 2010, Tcherpakov, 2013, Kisselev et al., 2012). These include:  
 MLN9708 and CEP18770 (Delanzomib) against multiple myeloma, non 
Hodgkin lymphoma, and solid tumours 
 Onyx0912 (Oprozomib) against haematological malignancies and solid 
tumours 
 Onyx0914 against autoimmune diseases 
 NPI-0052 (Marizomib/Salinosporamide A) against multiple myeloma 
Furthermore, proteasome inhibitors have shown promising results in animal 
models against autoimmune and inflammatory diseases like lupus nephritis, lupus, 
myasthenia gravis, polyarthritis, rheumatoid arthritis, irritant sensitivity, psoriasis, 
asthma, colitis etc. (Tcherpakov, 2013, Neubert et al., 2008, Ichikawa et al., 2012, 
Gomez et al., 2011, Fissolo et al., 2008, Palombella et al., 1998, Muchamuel et al., 
2009, Elofsson et al., 1999, Elliott et al., 2003, Elliott et al., 1999, Schmidt et al., 
2010, Basler et al., 2010, Kisselev et al., 2012). Recently, Novartis has shown that 
triazolo pyrimidine derivatives inhibit proteasome activity in protozoan parasites 
and filed a patent on using them for the treatment of diseases like leishmaniasis 
(Biggart et al., 2015). It is therefore reasonable to consider the application of 
proteasome inhibitors in anti-parasite drug discovery, as was patented in 1998 
(Daniel et al., 1998).  
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1.3.2 E1 enzymes as drug targets 
 
E1 enzymes are also known as ubiquitin activating enzymes. They catalyse the 
first step of the ubiquitination pathway in an ATP-dependent manner. Pyrazolidine 
compounds PR41 (Yang et al., 2007) and PYZD-4409 (Xu et al., 2010) have been 
shown to inhibit the activity of E1 enzymes. PR41 prevents the loss of p53 and can 
inhibit cytokine induced activation of NF-κB (Yang et al., 2007). It also blocks the 
activation of dendritic cells via IκBa/NF-κB and MKP1/ERK/STAT1 pathways thus 
showing potential as a therapeutic agent in autoimmune diseases (Chen et al., 
2014). PYZD-4409 preferentially induces cell death in malignant cell lines and 
prevents growth of primary AML cells (Xu et al., 2010). Benzothiazole and 
thiazole [5,5-b] pyridine compounds were also identified as inhibitors of E1 
enzyme (Look et al., 2005). 
 
1.3.3 E2 enzymes as drug targets 
 
E2 enzymes transfer the ubiquitin from the E1 enzymes to E3 enzymes. They 
regulate the length of the ubiquitin chains, processivity of chain formation and 
chain topology (reviewed in (Ye and Rape, 2009)). Different E2 enzymes could 
work together, with one being used for chain initiation and another for chain 
elongation with a specific topology (Windheim et al., 2008). Given the diverse 
regulatory functions of E2 enzymes, efforts are being made to find inhibitors of E2 
enzymes.  
 
hCDC34 is an E2 enzyme that works with cullin-ring (E3) ligases (CRLs) to 
ubiquitinate several targets. Ceccarelli et. al. (Ceccarelli et al., 2011) were working 
towards blocking the SCFskp2 (an E3 ligase) dependent ubiquitination of p27Kip1 as 
a way of therapeutic intervention into different cancer types (Nalepa et al., 2006, 
Frescas and Pagano, 2008). They identified CC0651, an allosteric inhibitor of 
hCDC34 that acts by stabilizing the E2-ubiquitin interaction and inhibits the 
proliferation of cancer cell lines (Ceccarelli et al., 2011, Huang et al., 2014).  
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Rad6B is another important E2 enzyme. It stabilizes β-catenin by ubiquitination 
(Shekhar et al., 2008). It also ubiquitinates proliferating cell nuclear antigen 
(PCNA) and hence plays an important role in translesion synthesis DNA repair 
(Hoege et al., 2002, Ulrich, 2005). Sanders et. al. (Sanders et al., 2013) found 
triazine analogs can inhibit the activity of endogenous RaD6B and can inhibit 
proliferation, colony formation and migration of a breast cancer cell line.  
 
Ubc13 or UBE2N is another E2 enzyme that has emerged as a very important 
therapeutic target due to its role in both oncology and immune disorders that have 
a combined market of USD 100 billion. Ubc13 catalyses K63-linked polyubiquitin 
chain formation (Hofmann and Pickart, 1999). It regulates p53 localization and 
activity (Laine et al., 2006, Topisirovic et al., 2009) and immune response 
(Fukushima et al., 2007, Yamamoto et al., 2006). Ubc13 catalyses the chain 
formation in the presence of either of the 2 cofactors: Uev1A or Mms2. Association 
with either cofactor regulates the chain length differently (Andersen et al., 2005). 
Also, Ubc13-Uev1A is involved in NF- κB activation, while Ubc13-Mms2 is 
involved in DNA repair (Andersen et al., 2005). Pulvino et. al. (Pulvino et al., 2012) 
identified NSC697923, a small molecule inhibitor of Ubc13-Uev1A which inhibits 
the constitutive NF-κB activation in diffuse large B-cell lymphoma (DLBCL) cells. 
Later, Cheng et. al. (Cheng et al., 2014) identified Ubc13 as a target in 
neuroblastoma (NB) cells due to its role in p53 sequestration. They found that 
NSC697923 induces apoptosis in NB cell lines by promoting nuclear localisation of 
p53 (Cheng et al., 2014). Several other inhibitors of the Ubc13-Uev1A complex are 
being developed (Tsukamoto et al., 2008, Scheper et al., 2010, Ushiyama et al., 
2012). 
 
1.3.4 E3 enzymes as drug targets 
 
E3 ligases catalyse the last step of the ubiquitination cascade. E3 enzymes bind to 
the E2-Ub complex and the substrate and this ubiquitin is then transferred from the 
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E2 to the substrate. As mentioned earlier, more than 600 E3 ligases are expressed 
in humans. These ligases are classified in three classes:  the really interesting new 
gene (RING) family, the RING between RING (RBR) family and the homologous to 
E6AP C-terminus (HECT) family (Deshaies and Joazeiro, 2009, Berndsen and 
Wolberger, 2014). RING family ligases bind to both the E2 and the target 
simultaneously and catalyse direct transfer of ubiquitin from the E2 to the target  
(Deshaies and Joazeiro, 2009). The RBR and HECT family ligases catalyse a two 
step transfer of ubiquitin: first, the ubiquitin is transferred from the E2 to the active 
site cysteine of the E3 ligase, followed by its transfer to the target (Spratt et al., 
2014, Huibregtse et al., 1995). E3 ligases offer greater specificity for drug 
discovery compared to E1 and E2 enzymes because they are relatively more 
specific for the target they ubiquitinate (Li et al., 2008). E3 ligases have been 
implicated in several therapeutic areas and hence are important targets (Cohen 
and Tcherpakov, 2010, Tcherpakov, 2013, Skaar et al., 2014, Metzger et al., 2012, 
Morrow et al., 2015, Lipkowitz and Weissman, 2011).  
 
An important example of an E3 ligase as a drug target is HDM2 or MDM2. In 
healthy cells, p53 and HDM2 form an auto-regulatory feedback to regulate one 
another’s levels (Patel and Player, 2008, Brooks and Gu, 2011).  Activation of p53 
by stress signals leads to upregulation of HDM2, which in turn blocks its 
transcriptional activity (Oliner et al., 1993) and marks it for degradation (Haupt et 
al., 1997, Honda et al., 1997, Kubbutat et al., 1997). Consequently, inhibition of 
HDM2 can lead to higher levels of p53 and exert anti-tumour effect. Several small 
molecules and peptides have thus been developed as inhibitors of HDM2 activity 
or HDM2-p53 protein-protein interaction (reviewed in (Patel and Player, 2008, 
Cohen and Tcherpakov, 2010, Tcherpakov, 2013)). Most notable of these are 
JNJ26854165 from Johnson & Johnson and Nutlin from Roche that are in clinical 
trials or in early development for different cancer types like solid tumours, multiple 
myeloma, neuroblastoma (Cohen and Tcherpakov, 2010, Tcherpakov, 2013, Patel 
and Player, 2008, Lakoma et al., 2015).  
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Inhibitors of Apoptosis proteins (IAPs) are another important class of E3 ligases 
from therapeutic intervention perspective. IAPs have been shown to be key 
regulators of several signal transduction pathways like NF-κB, JNK1, TGF-β, Myc, 
PI3K/Akt and the MAPK pathway (reviewed in (Flygare and Fairbrother, 2010)). 
Several small molecules targeting IAPs are in different phases of clinical trials 
against several cancer types. These include Ascenta Therapeutics/Debiopharma’s 
AT-406/Debio 1143, Genentech Inc./Curis’ GDC-0917/CUDC-427, Novartis’ 
LCL161, Tetralogic Pharmaceuticals’ TL-32711 and Aegera Therapeutics/Human 
Genome Sciences’ AEG40826/HGS1029 (Cohen and Tcherpakov, 2010, 
Tcherpakov, 2013, Flygare and Fairbrother, 2010, Hird et al., 2015). GDC-0152, 
another small molecule inhibitor of IAPs, showed toxicity (Hird et al., 2015). IAPs 
are also being pursued against autoimmune and inflammatory diseases, with 
Aegera pharmaceuticals have obtained a proof of concept data in rodent models of 
rheumatoid arthritis (Aegera’s website and (Tcherpakov, 2013)). Several other E3 
ligases like SMURF1, SCFSkp1, Cereblon, anaphase-promoting complex (APC) and 
Parkin are also being pursued as therapeutic targets (Tcherpakov, 2013). 
 
Different components of the ubiquitination machinery are thus validated targets in 
multiple therapeutic areas owing to their roles in regulation of various critical 
cellular pathways. With the examples of discovered and marketed small molecules, 
it is clear that all components of the ubiquitination machinery are tractable 
therapeutic targets in multiple therapeutic areas. Cross-talk between ubiquitination 
and other PTMs like phosphorylation (Yau and Rape, 2016) adds another layer of 
complexity to the ubiquitination process and offers additional ways of targeting 
ubiquitin-based regulation of cellular pathways. 
 
1.4 Deubiquitinases as drug targets 
 
As mentioned above, ubiquitination is a reversible post-translational modification, 
with deubiquitinases (DUBs) mediating the removal of ubiquitin from the target 
proteins. DUBs or ubiquitin-specific processing proteases are one of the largest 
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classes of proteases. The human genome encodes around 95 DUBs which are 
classified into five families based on the structure of their catalytic domain (Nijman 
et al., 2005). Four families are cysteine proteases: the ubiquitin-specific proteases 
(USP/UBP), the ovarian tumour (OTU) domain-containing proteases, the ubiquitin 
c-terminal hydrolases (UCH) and the Machado-Joseph domain (MJD) proteases. 
The fifth family is formed by metalloproteases, the JAMM (JAB1/MPN/MOV34) 
motif proteases. 
 
 
Figure 1.3 Roles of DUBs.  
DUBs play several roles in the maintenance of ubiquitin homeostasis in the cell 
(Komander et al., 2009). 
 
As shown in Figure 1.3 DUBs play several roles in the ubiquitination pathway 
(reviewed in (Komander et al., 2009)) and are thereby crucial regulators of diverse 
cellular processes like maintenance of monoubiquitin levels, substrate degradation 
at the proteasome, apoptosis and cell death, histone deubiquitination and hence 
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chromatin remodelling, cell cycle regulation, DNA damage repair response, 
activation of kinases, endocytosis, spermatogenesis and multiple signalling 
pathways (reviewed in (Komander et al., 2009, Reyes-Turcu et al., 2009, Wei et 
al., 2015)). Nearly 40 deubiquitinases are implicated in the regulation of cancer 
cells and are reviewed extensively in (Wei et al., 2015). Therefore, DUBs are being 
pursued as targets in several therapeutic areas like cancer, neurodegenerative 
disorders, haematological disorders, viral respiratory infections and bacterial 
gastroenteritis (reviewed in (Nicholson et al., 2014, Tcherpakov, 2013, Farshi et al., 
2015, D'Arcy et al., 2015, Ndubaku and Tsui, 2015, Colland, 2010, Daviet and 
Colland, 2008, Wei et al., 2015)). Some examples of deubiquitinases as targets 
and their identified inhibitors are discussed below. The structures of known DUB 
inhibitors are presented in Table 1.2. 
 
Table 1.2: Known inhibitors of human deubiquitinases and PLpro-a viral 
cysteine protease with deubiquitinase activity.  
Each compound is identified by a unique serial number. Also, mentioned are 
the commercial names, if available, and the DUBs they target. 
 
   
1 2 3 
  GRL0617 
Target DUB: PLpro Target DUB: PLpro Target DUB: PLpro 
   
4 5 6  
6-mercaptopurine 6-thioguanine  
Target DUB: PLpro Target DUB: PLpro Target DUB: PLpro 
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7 8 9 
 PR-619 Curcusone D 
Target DUB: PLpro Target DUB: Non selective Target DUB: Non selective 
   
10 11 12 
Pimozide ML323  
Target DUB: USP1/UAF1 Target DUB: USP1/UAF1 Target DUB: USP1/UAF1 
   
13 14 15 
C527 SJB3-019A 2-cyanopyrimidine 
Target DUB: USP1/UAF1 Target DUB: USP1/UAF1 Target DUB: USP1 and UCHL-3 
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16 17 18 
 HBX 41,108  
Target DUB: USP1/UAF1 DUB 
complex 
Target DUB: USP7 Target DUB: USP7 
   
19 20 21 
P5091 P22077  
Target DUB: USP7 and USP47 Target DUB: USP7 and USP47 Target DUB: USP7 and USP47 
   
22 23 24 
Spongiacidin C HBX19818  
Target DUB: USP7 Target DUB: USP7 Target DUB: USP7 
39 
 
   
25 26 27 
   
Target DUB: USP8 Target DUB: USP8 Target DUB: USP8 and USP7 
   
28 29 30 
  EOAI3402143 
Target DUB: USP8 and USP7 Target DUB: USP8 binder Target DUB: USP9X 
   
31 32 33 
Spautin-1 Mitoxantrone b-AP15 
Target DUB: USP10 and USP13 Target DUB: USP11 Target DUB: UCH-L5 and USP 
14 
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34 35 36 
b-AP15 analogue VLX1579, b-AP15 analogue IU2-6 
Target DUB: UCH-L5 and USP 
14 
Target DUB: UCH-L5 and USP 14 Target DUB: USP14 
   
37 38 39 
Compound 1570 in patent US 
20140228354 A1 
IU1 GSK2643943A 
Target DUB: UCH-L5 and USP 
14 
Target DUB: USP14 Target DUB: USP20 
   
40 41 42 
 Δ12-PGJ2  
Target DUB: USP30 Target DUB: UCHL1 Target DUB: UCHL1 
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43 44 45 
Z-VAE(OMe)-FMK   
Target DUB: UCHL1 Target DUB: UCHL1 Target DUB: UCHL1 
   
46 47 48 
   
Target DUB: UCHL1 Target DUB: UCHL1 Target DUB: UCHL3 
   
49 50 51 
   
Target DUB: UCHL3 Target DUB: UCHL3 Target DUB: UCHL3 
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52 53 54 
   
Target DUB: UCHL3 Target DUB: UCHL3 Target DUB: UCHL3 
   
55 56 57 
 PX-478 WP1130 
Target DUB: RPN11 Target DUB: Not known Target DUB: USP14, UCHL5, 
USP9x, USP5 
 
USP7 
Deubiquitinase activity of USP7 stabilises HDM2 which in turn marks p53 for 
degradation (Cummins et al., 2004, Li et al., 2004). Inhibition of USP7 can lead 
thus to p53 stabilisation and tumour suppression. USP7 has also been shown to 
downregulate the activity of a transcription factor FOXO4 and thus regulates FOXO 
mediated stress response (van der Horst et al., 2006). Several attempts have been 
made for the identification of inhibitors of USP7. The first identified inhibitor of 
USP7 was HBX 41,108 (17), developed by Hybergenics (Colland et al., 2009). It is 
a cyano-indinopyrazine derivative and is an uncompetitive reversible inhibitor of 
USP7. It was shown to stabilize p53 and induce p53 mediated apoptosis in cancer 
cell lines (Colland et al., 2009). P5091 (19) and its analogues are another series of 
inhibitors of USP7 that were developed by Progenra (Chauhan et al., 2012). P5091 
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is a trisubstituted thiophene with dichlorophenylthio, nitro and acetyl substitutions. 
It was shown to induce apoptosis in multiple myeloma cells and also overcome 
resistance against known therapies (Chauhan et al., 2012). HBX 19,818 (23) and 
HBX 28,258 are two specific inhibitors of USP7 developed by Hybergenics. They 
contain tetrahydroacridine core (Reverdy et al., 2012).  
 
USP14 and UCHL5 
USP14 and UCHL5/Uch37 are two deubiquitinases that associate reversibly to the 
19S regulatory particle of the proteasome (Yao et al., 2006, Lee et al., 2010, 
Borodovsky et al., 2001). b-AP15 (13) is a small molecule inhibitor of the 
proteasome activity that acts via the inhibition of USP14 and UCHL5 (D'Arcy et al., 
2011). b-AP15 induces p53 independent apoptosis (Erdal et al., 2005), causes 
tumour cell apoptosis and inhibits tumour growth in vivo (D'Arcy et al., 2011) and 
shows inhibitory effect on multiple myeloma cell lines and patient cells (Tian et al., 
2014). Auranofin is a gold containing compound that has been used for treatment 
of rheumatoid arthritis since several decades. Recently auranofin was shown to 
inhibit proteasome activity via the inhibition of USP14 and UCHL5. This 
suppresses tumours in vivo and causes cytotoxicity in AML patient cells (Liu et al., 
2014). WP1130 (57) or degrasyn is a small molecule identified from a screen for 
inhibitors of cytokine induced activation of JAK/STAT pathway (Bartholomeusz et 
al., 2007a). It is a second-generation tyrphostin derivative (Bartholomeusz et al., 
2007b). It has been shown to have apoptotic, anti-tumour and/or anti proliferative 
effects against chronic myelogenous leukaemia (Bartholomeusz et al., 2007b), 
melanoma (Bartholomeusz et al., 2007a) and mantle cell lymphoma (Pham et al., 
2010). It has been shown to be a partially selective deubiquitinase inhibitor 
targeting four deubiquitinases namely USP14, UCHL5, USP9X and USP5 (Kapuria 
et al., 2010).  
 
USP9X 
USP9X/Fam, a deubiquitinase, has been implicated in the regulation of several 
cellular processes. For example, it plays a role in the positive regulation of the 
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TGF-β signalling (Dupont et al., 2009), stabilizes β-catenin (Taya et al., 1999), 
stabilizes Mcl1 (myeloid cell leukaemia 1) leading to increased survival of tumour 
cells (Schwickart et al., 2010) and promotes polarity and self-renewal in stem cell 
derived neural progenitors (Jolly et al., 2009). USP9X knockdown can have 
therapeutic effects in case of B-cell acute lymphoblastic leukaemia (Zhou et al., 
2015) and hepatocellular carcinoma (Hu et al., 2015) while its activation can be 
beneficial for the treatment of pancreatic ductal adenocarcinoma (Perez-Mancera 
et al., 2012). As mentioned above WP1130 (57) has been shown to inhibit USP9X 
activity (Kapuria et al., 2010). Another identified inhibitor of USP9X activity is 
EOAI3402143 (30) which was shown to induce tumour cell apoptosis and 
suppressed growth of tumours in mice grafted with multiple myeloma tumours 
(Peterson et al., 2015). 
 
PLpro 
PLpro is a cysteine protease in the severe acute respiratory syndrome coronavirus 
(SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). 
PLpro has a deubiquitinating activity against the host proteins. This 
deubiquitinating activity of PLpro inhibits the STING (stimulator of interferon genes) 
signalling in host cells leading to the disruption of the innate antiviral immune 
response (Sun et al., 2012). Thus, PLpro is considered an antiviral target. 6-
mercaptopurine (4) and 6-thioguanine (5) were identified as inhibitors of both 
SARS-CoV PLpro and MERS-CoV PLpro (Chou et al., 2008, Cheng et al., 2015). 
GRL0617 (3) is another identified inhibitor of SARS-CoV PLpro (Ratia et al., 2008). 
It is a competitive inhibitor with sub-micromolar potency (IC50 0.6 µM). Several 
inhibitors with higher potencies have been developed by modifying GRL0617 
(Kemp, 2016).   
 
USP30 
USP30 has been shown to be a therapeutic target against Parkinson’s disease. In 
neurodegenerative diseases like Parkinson’s disease, mitochondrial defects and 
dysfunction play a key role. Parkin, an E3 ligase, marks damaged mitochondria for 
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mitophagy by ubiquitinating outer mitochondrial membrane proteins (Narendra and 
Youle, 2011). USP30 localises to mitochondria and opposes Parkin mediated 
mitophagy by deubiquitinating outer membrane proteins (Bingol et al., 2014, 
Cunningham et al., 2015). A diterpenoid derivative, 15-oxospiramilactone (40), 
was shown to induce mitochondrial fusion and restore mitochondrial network (Yue 
et al., 2014). It was identified to inhibit USP30 (Yue et al., 2014).  
 
Even though it has proven challenging to develop small molecule inhibitors with 
specificity against DUBs, there are several successful examples to conclude that 
drug discovery efforts against DUBs have potential and it is worth pursuing them 
as targets.  
 
1.5 TbrDUB1 is essential for parasite survival 
 
While DUBs present an attractive and novel class of tractable targets in a wide 
range of therapeutic areas, they have remained largely unexplored in parasitic 
diseases. In a recent work, Rodenko et. al. identified at least 21 DUBs 
(unpublished data) in T. brucei by activity-based protein profiling (ABPP) (de Jong 
et al., 2012). This was followed by RNAi knockdown screen to identify if any DUB 
is essential for the survival of the parasite. It was seen that when the RNAi was 
induced against TbrDUB1, one of the 21 TbrDUBs, it led to parasite clearance both 
in vitro and in vivo within 48h, suggesting that this DUB is essential for parasite 
survival (Figure 1.4 with permission from Rodenko, B. et. al. unpublished data).  
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Figure 1.4 TbrDUB1 is essential for parasite survival.  
(a) in vitro RNAi knockdown shows that TbrDUB1 knockdown is trypanocidal 
(b) in vivo RNAi knockdown of TbrDUB1 in parasites infecting mice (n=2 per 
group) shows that the parasitemia is again cleared within 48h. (--------- parasite 
detection limit: 104 cells/mL) 
 
 
 
Figure 1.5 TbrDUB1 activity is essential for parasite survival.  
(a) A recoded TbrDUB1 leads to phenotype rescue while (b) and (c) 
catalytically null mutants of TbrDUB1 lead to parasite clearance within 48 
hours. 
 
This was followed by the generation of mutant parasites that either express 
catalytically active or inactive TbrDUB1. In catalytically null mutants the active site 
cysteine of TbrDUB1 was mutated to either serine or alanine. Parasites expressing 
catalytically inactive TbrDUB1 die within 48h while parasites expressing wild-type 
TbrDUB1 are unaffected (Figure 1.5). These experiments clearly establish that not 
just the expression, but also the activity of TbrDUB1 is essential for the survival of 
the parasite. In addition to the strong genetic validation of the TbrDUB1 as a 
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potential target, Rodenko et.al. also screened a small library of small-molecule 
pan-DUB inhibitors and found several molecules with trypanocidal activity. This 
observation chemically validates DUBs as a class as drug targets in T. brucei.   
 
In summary, these results indicate that DUBs are chemically validated target class 
in T. brucei and that TbrDUB1 is essential for parasite survival. These evidence are 
thus sufficient to launch a drug discovery effort targeting TbrDUB1.   
 
1.6 The process of drug discovery  
 
Drug discovery is a complex interdisciplinary field involving numerous disciplines 
with biology and chemistry at the core working together to identify novel 
treatments. The cost associated with bringing a new treatment to the market is 
estimated at 2.6 billion US dollars (DiMasi et al., 2016, DiMasi et al., 2003, Munos, 
2009). Additionally, the cost per new molecular entity has been increasing 
exponentially since 1950 at an annual rate of 13.4% (Munos, 2009). To get a 
perspective, nearly 1200 drugs have been approved by the FDA between 1950 
and 2008, an average of 21 drugs per year (Munos, 2009). On an average time it 
takes more than 13 years from early-stage studies to bringing the drug to the 
market (Paul et al., 2010). The process of drug discovery typically starts with the 
identification and validation of a target which could be molecular or cellular. This is 
followed by the identification of a small molecule or a biopharmaceutical that has 
the desired activity on the target, i.e. either inhibits or activates it depending on the 
therapeutic need. The small molecules at this stage are called hits. The next step 
involves medicinal chemistry efforts to optimise the potency, selectivity, 
pharmacokinetics and pharmacodynamics of these molecules at which stage they 
are declared as ‘candidate’. These candidates are then tested in preclinical studies 
in vitro and/or in animals for their safety and optimum dosage for the first-time-in-
humans. If successful in preclinical studies, the compound goes to first-time-in-
human trials (phase I) to determine the safe dosage range and to assess the drug 
safety in a small group of healthy individuals. In phase II trials, the efficacy of the 
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drug is tested and the safety is further evaluated, involving up to hundreds of 
patients. Phase III trials are conducted in a much larger group of patients which 
could be from 300 to 3000 and can last up to 4 years. The efficacy, especially 
compared to already marketed treatments, and safety and side effects are tested in 
this phase. If successful, the drug is approved by regulatory bodies for treatment of 
the condition it was tested for. Post the launch, during the phase IV of the trials, 
further information is gathered about the safety, side effects, long term risks and 
benefits and efficacy.  
 
The work in this thesis is focused on the early phases of drug discovery up to hit 
selection for TbrDUB1. To identify small molecule inhibitor against the TbrDUB1 
several approaches can be taken and each has its advantages and disadvantages 
in terms of cost, speed, flexibility and the quality of the candidates delivered. The 
different approaches include full-diversity high-throughput screening (HTS), 
encoded library technology (ELT) screening, focused set screening, fragment 
based screening, virtual screening and knowledge-based or rational drug design. 
Since the structure of TbrDUB1 is yet to be resolved, virtual screen, fragment 
based screening and rational drug design are not the approaches that we could 
take. An ELT screen identifies compounds that bind to the target with or without 
any effect on the activity of the target. A biochemical high-throughput screen will 
however focus on identifying inhibitors of enzyme activity. Starting with a diverse 
chemical library increases the chances of identifying tractable hits. A focused set is 
a set of compounds that could hit a target class. A HTS library contains all the 
compounds from focused sets, hence if feasible, HTS will have higher chances of 
success, because a larger diversity of compounds is tested. We focused our efforts 
on HTS at this stage and ELT screen could be carried out at a later stage, if 
required. It is financially not viable to apply all screening approaches to each target 
and hence often a choice has to be made based on feasibility and availability of 
tools. HTS has become a popular approach to early drug discovery over the past 
two decades and several marketed drugs originate from HTS campaigns 
(Macarron et al., 2011, Swinney and Anthony, 2011). HTS involves screening a 
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library of small molecules against a target- using either biochemical or cell-based 
assays. The outcome of a HTS not only depends on the nature of the target and 
the quality of the assay, but is also heavily influenced by the nature of the 
screening library. The estimated number of molecules that could be theoretically 
synthesized ranges between 1020 and 1060. In comparison, the number of seconds 
that have passed since the Big Bang is around 1017 (Valler and Green, 2000). As it 
is impossible to either synthesize or test the vast numbers of molecules, 
pharmaceutical companies build and expand their libraries with a focus on 
compound diversity in order to sample a broad chemical space. Several 
pharmaceutical companies have libraries up to one million compounds and only 
very few have larger collections. GlaxoSmithKline (GSK) has a HTS library of 
around 1.7 million compounds. This library has been improved over decades to be 
chemically diverse and is enriched in ‘drug-like’ molecules with desirable 
physicochemical properties. The importance of physicochemical properties is 
discussed in section 5.4. 
 
1.7 The aim of the thesis 
 
The questions that are explored in this thesis are:  
 
Can we find small molecule inhibitors of TbrDUB1 that are specific and cidal 
against T. brucei? And are the hits obtained as an outcome of these efforts cidal 
against T. cruzi and/or L. donovani? 
 
Chapter 3 of this thesis describes the enzyme purification and assay development. 
Chapter 4 describes the primary HTS of GSK’s small molecule library (~1.7 million 
compounds) against TbrDUB1 in a biochemical assay. Chapter 5 describes the 
process of hit characterisation and prioritisation through multiple secondary 
biochemical assays. The prioritised hits are tested in whole-cell assays against T. 
brucei and the closely related parasites T. cruzi and L. donovani to identify 
compounds with cross-species activity. 
  
 
 
 
Chapter 2 Materials and Methods 
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2.1 Buffers and culture media 
His trap buffer A 
40 mM Tris pH 7.6 
300 mM NaCl 
10 mM imidazole 
5 mM βME (add fresh) 
pH 7.6 
Filter through 0.2 micron filter 
 
His trap buffer B 
40 mM Tris pH 7.6 
300 mM NaCl 
500 mM imidazole 
5 mM βME (add fresh) 
pH 7.6 
Filter through 0.2 micron filter 
 
SEC buffer 
20 mM Tris pH7.6 
50 mM NaCl 
5 mM βME (add fresh) 
Autoclave 
 
Dulbeco’s PBS 
Potassium Chloride 2.7 mM 
Potassium Phosphate monobasic (KH2PO4) 1.47 mM 
Sodium Chloride 137.9 mM 
Sodium Phosphate dibasic (Na2HPO4-7H2O) 8 mM 
 
4X Laemmli Sample Buffer 
250 mM Tris-HCl, pH 6.8 
4% Lithium dodecyl sulfate (LDS) 
40% (w/v) glycerol 
0.018% bromophenol blue 
10% v/v (1.42 M) β mercaptoethanol 
 
SDS Tank buffer 
25 mM Tris 
192 mM glycine  
0.1% SDS  
pH 8.6 
 
DUB assay buffer 
50 mM Tris pH 7.6  
50 mM NaCl 
1 mg/mL (1.626 mM) CHAPS  
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0.132 mg/mL (2 μM) dBSA  
2 mM DTT 
Filter through 0.2 micron filter. Degas for at least 10 minutes. 
 
Sans DTT assay buffer 
50 mM Tris pH 7.6  
50 mM NaCl 
1 mg/mL (1.626 mM) CHAPS  
0.132 mg/mL (2 μM) dBSA  
Filter through 0.2 micron filter. Degas for at least 10 minutes. 
 
SOD/Catalase assay buffer 
50 mM Tris pH 7.6  
50 mM NaCl 
1 mg/mL (1.626 mM) CHAPS  
0.132 mg/mL (2 μM) dBSA 
10 μg/mL SOD 
500 μg/mL catalase 
2 mM DTT 
Filter through 0.2 micron filter. Degas for at least 10 minutes. 
 
L-cys assay buffer 
50 mM Tris pH 7.6  
50 mM NaCl 
1 mg/mL (1.626 mM) CHAPS  
0.132 mg/mL (2 μM) dBSA  
2 mM L-cysteine 
Filter through 0.2 micron filter. Degas for at least 10 minutes. 
 
Resazurin assay buffer 
50mM Hepes 
50mM KCl 
pH 7.5 
 
hCTSB assay buffer 
100 mM Sodium Acetate  
150 mM NaCl  
5 mM EDTA 
1 mM CHAPS 
40 µM L-cysteine 
pH 5.5 
 
T. brucei culture medium 
1mM Hypoxanthine  
0.16 mM Thymidine  
1.5 mM L- Cysteine 
0.05 mM Bathocuproinedisulfonic acid disodium salt 
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1 mM Sodium pyruvate solution 
0.0014% 2-Mercaptoethanol 
Make up volume with Iscove’s Modified Dulbecco’s Medium 
pH 7.5 
Filter sterilize through 0.2 micron filter 
 
T. brucei complete culture medium 
90% v/v T. brucei culture medium 
10% v/v foetal bovine serum (tetracycline free- Gibco 26140-079). 
 
HepG2 cell culture medium 
Eagles MEM with L-Glutamine and Earle's Salts 
10 % FBS 
1% of 100X non essential amino acid solution 
 
 
2.2 Materials 
 
2.2.1 Chemical reagents 
 
4x Laemmli Sample Buffer Biorad 161-0747; 7-Amino-4-(trifluoromethyl)coumarin 
Sigma 248924; Bathocuproinedisulfonic acid disodium salt Sigma B1125-500mg; 
BCA Protein Assay Reagent Pierce 23225; Bradford's reagent Sigma B6916; BSA 
Sigma A3803; Catalase Sigma C100; Cellfectin II Life technologies 10362-100; 
CellTitre-Glo luminescent cell viability assay reagent Promega G7571; CHAPS 
Sigma C-3023; Digitoxin Sigma D-5878; DMSO Sigma 34943; DTT Sigma D-0632; 
E-64 Sigma E3132; Eagles MEM with L-Glutamine and Earle's Salts Gibco 31095-
052; EDTA Sigma E7889; Gentamicin solution (50 mg/mL) Life technologies 
15750-037; Hepes Sigma H-3375; HyClone Sfx-Insect cell culture medium Fisher 
scientific SH30278LS; Hydrogen peroxide Sigma H1009; Hygromycin B, 
Streptomyces sp. Calbiochem 400050; Hypoxanthine Sigma H9636-5G; Imidazole 
Sigma I0125; Instant blue Expedeon ISB1L; Iodoacetamide Sigma I1149; IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) Sigma I6758; Iscove's Modified Dulbecco's 
medium Gibco 21980-065; Kanamycin sulfate Sigma K1377; KCl Merck 104936; L-
Cysteine Sigma C7352; Magic Mark XP western standards Life technologies 
LC5603; Mini-PROTEAN® TGX Stain-Free™ Precast Gels Biorad 4568093 or 
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4568096; NaCl Sigma S5886; Non essential amino acid solution Gibco 11140-068; 
Novex Tris glycine gels Life technologies EC60285BOX; dPBS Gibco 14190-136; 
Phleomycin from Streptomyces verticillus Sigma P9564; Phorbol 12-myristate 13-
acetate (PMA, Sigma);  Precision plus protein dual colour standards Biorad 161-
0374; QIAprep spin miniprep kit Qiagen 27104; Resazurin Mol probes R12204; 
Resazurin Sigma R7017; Resorufin Sigma R3257; SeeBlue Plus2 molecular 
weight markers Life technologies LC5925; Super Optimal broth with Catabolite 
repression (SOC) medium Life technologies 15544-034; Sodium acetate Ambion 
AM9740; Sodium pyruvate solution Sigma S8636-100ml; Superoxide dismutase 
Sigma S5389; SuperSignal West Pico Chemiluminescent Substrate Pierce 34077; 
Tetracycline hydrochloride Sigma T7660; Thymidine Sigma T1895-1G; 
Tris/Glycine/SDS 10X electrophoresis buffer Biorad 1610732 or Sigma T7777; 
Trizma pH 7.6 Sigma T2444; Tween 20 Sigma P5927; Ubiquitin bound to 5-
TAMRA or Ub-FP substrate UbiQ bio Ubi-012; XGal Promega V394A; Z-Phe-Arg-
AFC Bachem; β mercaptoethanol Sigma M3148. 
 
2.2.2 Biological and Molecular reagents 
 
Anti-myc tag antibody, clone 4A6, alexa fluor® 555 conjugate Merck Millipore 16-
225; Anti-polyhistidine-peroxidase monoclonal antibody produced in mouse- clone 
HIS-1 Sigma A7058; E. coli positive control whole cell lysate Abcam ab5395; Fetal 
Bovine Serum, qualified, US origin (Tet free) Gibco 26140-079; HepG2 cells ATCC 
HB-8065; MAX Efficiency® DH10Bac™ Competent Cells Invitrogen 10361-012; 
Spodoptera frugiperda pupal ovarian tissue (Sf9) cell line from European Collection 
of Authenticated Cell Cultures (ECACC) 89070101. 
 
2.2.3 Equipment and materials 
 
1536-well, black, medium-binding plates (Greiner 782076); 1536-well CELLSTAR®, 
HiBase, tissue culture treated, flat bottom, white microplates (Greiner 782073) with 
sterile lids (Greiner 656191); 384 well low volume black plates (Greiner 784076); 6 
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well plate Fisher Scientific TKT-520-030T; Agilent direct drive robot; AKTA pure 25 
from GE coupled to a fraction collector F9-C and controlled by Unicorn 6.3 ; Baffled 
Polycarbonate Erlenmeyer Flask with Vent Cap Corning 431405, 431407, 431401, 
431403 and 431253; Beckman Allegra 25R centrifuge; CASY cell counter (Roche 
diagnostics); Cedex AS20 cell counter (Innovatis); Chemidoc MP (Biorad); 
disposable hemocytometer (Incyto DHC-N01-5); Echo liquid handling system 
(Labcyte Inc.); EnVision™ 2104 multilabel reader with laser (Perkin Elmer); Galaxy 
R CO2 incubator (R S biotech); Heraeus Cytomat incubator; HiLoad 16/600 
Superdex 200 pg (GE healthcare 28989335); His-trap HP 5 mL columns (GE 
healthcare 17-5248-02); Life technologies iBlot system with gel transfer stacks with 
PVDR membrane (Life technologies IB401002); Thermo Electron Multidrop Combi 
nL low volume reagent dispenser; Thermo Electron Multidrop® Combi using a 
small tube metal tip dispensing cassette (Cat # 24073295); Wallac ViewLux 1430 
ultraHTS microplate imager (Perkin Elmer). 
 
 
2.3 Methods 
 
2.3.1 Protein generation 
 
2.3.1.1 Expression in insect cells 
 
MAX Efficiency® DH10Bac™ competent cells were used to generate the bacmids. 
50 µL of DH10Bac cells were thawed on ice for 5 to 10 minutes and 0.75 µg of 
pFastbac construct DNA was added to these DH10Bac cells and left on ice for 15 
minutes. A 45 second heat shock at 42 °C was then given to the cells which were 
then left on ice for 5 minutes. 900 μL of S.O.C. medium was added and cells were 
incubated for 4 h at 37 °C. Different dilutions, viz., 1/1000, 1/100, 1/10 and the rest 
of the cells, were plated on LB agar plates containing 50 μg/mL kanamycin, 10 
μg/mL tetracycline, 7 μg/mL gentamicin, 100 μg/mL X-gal and 40 μg/mL IPTG. The 
plates were incubated at 37 °C for 24 hours and some blue and white colonies 
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were selected and restreaked on fresh plates to confirm the colour. The bacmid 
was obtained from these colonies using the Qiagen mini prep kit following the 
manufacturer’s instructions. These bacmid were used to transfect insect cells. 
 
Insect cells (Sf9) were maintained in logarithmic growth phase by maintaining the 
cell counts between 3 x 105 and 7 x 106 cells/mL at 27 °C, 100-120 rpm in 
maximum 1/3 full Erlenmeyer flasks. The cells were maintained in HyClone Sfx-
Insect cell culture medium. To transfect the insect cells, 0.45 x 106 Sf9 cells in 
2 mL of Hyclone medium were seeded per well in a sterile 6-well tissue culture 
plate (Fisher Scientific TKT-520-030T). Two additional control wells were always 
kept: cellfectin control (cells + CellFectin II + medium) and cells only control (cells + 
medium). The plate was incubated 27 °C for 1 h to allow cells to attach. During this 
incubation period, 6 µL CellFectin II reagent was added to 200µL Hyclone medium. 
5 µL bacmid DNA was added to this mixture and incubated for at least 15 min. at 
room temperature. 800 µL Hyclone medium was added to this mixture. Once the 
Sf9 cells were properly attached to the surface of the 6 well plates, the medium 
was removed from the top and the 1mL DNA/CellFectin II mixture was added to the 
cells. The plates were incubated for 5 h at 27 °C. Then the transfection mixture 
was removed and cells were washed with 2 mL medium before adding the final 2 
mL medium. The plates were placed in a humid environment in a box and 
incubated for five days at 27 °C. After five days, the supernatant was collected. 
This was the P0 stock which was used to generate P1. 
 
To make P1 baculovirus, 2% v/v P0 virus was mixed with typically 50 to 75 mL SF9 
cells at 1x106cells/mL. The cell count and viability was checked every day using 
Cedex AS20. On the day five the P1s were harvested by centrifuging the culture at 
3500 rpm for 20 minutes to pellet the Sf9 cells. The supernatant is the P1 virus 
stock which was stored at 4 °C protected from light. 
 
1/1000 v/v dilution of P1 virus was used to infect SF9 cells at a cell count of 2x106 
cells/mL. The cells were monitored for increase in diameter indicating successful 
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infections. The cells were harvested 48 hours post infection and frozen at -80 °C till 
used for lysis for protein purification. 
 
2.3.1.2 Cell lysis 
 
The insect cell pellet was resuspended in his trap buffer A at approximately 180 mg 
cells/mL. Cell lysis was carried out by sonication on ice at 40% amplitude with a 
pulse of 30 seconds on and 59 seconds off with total pulse on time of 10 minutes. 
Following this, the lysate was ultracentrifuged for 90 mins at 4 °C at 300,000 g on a 
Beckman coulter ultracentrifuge XL90 using Type 70 Ti rotor with Beckman Coulter 
centrifuge tubes number 355618. The supernatant was collected and used to purify 
TbrDUB1. 
 
2.3.1.3 Affinity purification 
 
The supernatant obtained after lysis of insect cell pellet was subjected to affinity 
purification using a GE His Trap HP 5 mL column coupled to a GE AKTA pure.  
The column was first prepared for the purification run according to manufacturer’s 
instructions. This included 5 column volume (CV, 1 CV is 5 mL) wash with 20% 
ethanol, 5 CV wash with water, 5 CV wash with his trap buffer B without reducing 
agent and 10 CV wash with his trap buffer A without reducing agent. Following this, 
before loading the sample, the column was equilibrated with 5 CV of his trap buffer 
A. UV 280 was monitored throughout the run. The lysate was then applied to the 
column at a flow rate of 5 mL/min. The column was washed with 19.8 mM 
imidazole (obtained by 98 : 2 buffer A : buffer B mix) for at least 25 CV. The UV280 
readout was monitored and the washes were maintained till the readout became 
stable indicating that all non specific proteins have washed out. For elution the 
direction of the flow was reversed to obtain a concentrated protein stock when the 
protein elutes. A shallow linear gradient followed by a step gradient was used to 
elute the bound proteins. The gradient used is presented in Table 2.1. 1 mL 
fractions were collected in 96 well plates. 
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Table 2.1: Elution gradient for affinity purification.  
A combination of linear and step gradients was used for cleaning the column 
and eluting the bout TbrDUB1. (CV-column volume).  
 
% buffer B Gradient Type Length of step (CV) Effective imidazole conc. (mM) 
2-4% Linear 5  19.8-29.6 
10 % Step 10 59 
30% Step 5 157 
60% Step 5 304 
100% Step 5 500 
 
 
2.3.1.4 Size exclusion chromatography 
 
A GE HiLoad 16/600 Superdex 200 pg column coupled to a GE AKTA pure was 
used for size exclusion chromatography. The column was first equilibrated with 2 
column volumes of the SEC buffer before starting the run. The sample was loaded 
in to a 10 mL superloop by manual loading. Following the loading of the sample on 
the column, an isocratic 2 column volume elution at a flow rate of 0.5 mL/min (15 
cm/h) was used to obtain high resolution. 1 mL fractions were collected in 96 well 
plates. UV280 was monitored throughout the run. The purified TbrDUB1 was 
quantitated using absorbance at 280 nm on a nano-drop using the Bear- Lambert 
law: 
        
Where A is the Absorbance at a given wavelength, ε is the absorption coefficient at 
a given wavelength (ε=688180 for TbrDUB1 at 280 nm), l is the path length and c 
is the concentration of the sample (MW= 66 kDa). 
 
2.3.1.5 SDS-PAGE and western blotting 
  
SDS-PAGE was used to resolve proteins in different fractions. For SDS-PAGE 10 
or 15 well 4-20% tris-glycine gels were used. For gels to be stained with Instant 
blue, SeeBlue Plus2 molecular weight markers or Precision plus protein dual 
colour standards were typically used. For gels used for western blotting, Magic 
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Mark XP western standards were used. Samples were prepared by diluting 
appropriately in 4x Laemmli Sample Buffer and then heating them at 95 °C for 10 
minutes. Following this, the samples were resolved on the gel. The proteins were 
first allowed to stack at a constant voltage of 100V till a uniform front was obtained. 
Then the proteins were resolved at a constant voltage of typically 200V. 
 
For western blotting the iBlot western blotting system from Life technologies was 
used. We used the ready to use kit following manufacturer’s instructions. A 
7 minute transfer protocol was used. The membrane was then blocked with 5% 
non-fat milk for at least 2 hours. This was followed by 3 washes of 5 minutes each 
with 0.05% tween-20 in PBS (PBST). The membrane was then probed with 1:2000 
dilution of anti-his antibody in PBS. The membrane was washed again thrice for 5 
minutes each with PBST. SuperSignal west pico chemiluminescent substrate was 
used to develop the blot and the blot image was obtained using 
chemiluminescence mode (no illumination, no excitation filter) on Biorad 
Chemidoc MP. 
 
2.3.2 Assay development 
 
2.3.2.1 Buffer optimisation 
 
To optimize the buffer for maximum assay signal window different additives were 
tested. Different additives and the highest concentration tested were: EDTA 
100 mM, heat-denatured BSA (dBSA 2.2 mg/mL), Pluronic Acid 2.5%, CHAPS 
6 mM, Tween-20 60 µM, Tween-80 12 µM, Triton X-100 400 µM and DTT 1 M. 
Eleven concentrations of each of these additives at ½ dilution were tested. Three 
different assay buffers were used because a detergent and a reducing agent are 
essential for enzyme activity. Buffer 1 was 50 mM Tris pH 7.6, 1 mg/mL CHAPS, 2 
mM DTT and was used to test EDTA and dBSA. Buffer 2 was 50 mM Tris pH 7.6, 2 
mM DTT and was used to test different detergents. Buffer 3 was 50 mM Tris pH 
7.6, 1 mg/mL CHAPS which was used to test DTT concentration. The test was 
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performed in a 384 well, low volume, black plates (Greiner 784076). The plate map 
is shown in Figure 2.1. 
 
 
Figure 2.1: Plate map for buffer optimisation.  
Different additives were tested for their effect on the TbrDUB1 activity, 
measured by observing the assay window obtained. Each additive was tested 
at eleven ½ dilutions, in duplicates. For each conc. of additive that was tested, 
a no enzyme control was also tested.  
 
The final assay volume was 15 µL and the enzyme and substrate concentrations 
were 1.875 nM and 100 nM respectively. 5 µL each of 3X additive in respective 
buffer, 3X enzyme and 3X substrate were dispensed in this order to start the 
reaction. Each concentration was tested in duplicates. No enzyme control, in 
duplicates, was included for each concentration of each additive. The plates were 
then read on EnVision™ 2104 multilabel reader with laser. The excitation filter 
used was 531 ± 25 nm (Perkin Elmer BODIPY TMR FP 531 bar code 105). The 
emission filters for the s and p channels were 579 ± 25 nm: Perkin Elmer TAMRA 
FP S-pol 579 bar code 245 and Perkin Elmer TAMRA FP P-pol 579 bar code 246 
respectively. The mirror module used was D555fp/D595 (Perkin Elmer BODIPY 
TMR FP Dual Enh bar code 682). Other settings used for the optics were 
measurement height 8.91 mm, number of flashes 10, PMT gain 325, second PMT 
gain 225, G-factor 0.8 and excitation light 60%. 
 
 
 
Starting conc. Fold dilution 1 0.5 0.25 0.125 0.063 0.031 0.016 0.008 0.004 0.002 0.001 0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
EDTA A                        
in Buffer 1 100mM B                        
dBSA C                        
in Buffer 1 6.6 mg/ml D                        
1 x CMC 0.5 x CMC 0.25 x CMC 0.125 x CMC 0.062 x CMC 0.031 x CMC 0.016 x CMC 0.008 x CMC 0.004 x CMC 0.002 x CMC 0.001 x CMC 0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Pluronic Acid E                        
in Buffer 2 3% F                        
CHAPS G                        
in Buffer 2 6mM H                        
Tween-20 I                        
in Buffer 2 60µM J                        
Tween-80 K                        
in Buffer 2 12µM L                        
Triton X-100 M                         Original
in Buffer 2 400µM N                         Format
E - E E - E E - E E - E E - E E - E E - E E - E E - E E - E E - E E - E
1 0.5 0.25 0.125 0.063 0.031 0.016 0.008 0.004 0.002 1E-03 0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
DTT O                        
in Buffer 3 1M P                        
E - E E - E E - E E - E E - E E - E E - E E - E E - E E - E E - E E - E
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2.3.2.2 Product standard curve 
 
The product standard curve was performed in 1536-well, black, medium-binding 
plate (Greiner 782076).  Stock solution of product (5-TAMRA) at 10 mM and 
substrate (Ub-FP) at 100 µM were prepared in DMSO. Further dilutions were 
prepared in the DUB assay buffer and 2.5 µL each of product and substrate 
dilutions were mixed to obtain different product to substrate ratios. The final 
substrate and product concentrations ranged between 0 to 100 nM. The plate was 
read on two different EnVision™ 2104 multilabel readers with laser. The excitation 
and emission filters and the mirror module used were the same as described 
above. Other settings used for the optics for the first instrument were measurement 
height 8.91 mm, number of flashes 10, PMT gain 305, second PMT gain 225, G-
factor 0.8 and excitation light 60%. These settings different for the second EnVision 
were measurement height 11 mm and G-factor 1. 
 
2.3.2.3 Determination of kinetic parameters 
 
The experiment was performed in a 384-well, black, medium-binding plate (Greiner 
784076) at a final assay volume of 15 µL. Different concentrations of substrate viz. 
1, 5, 10, 50, 100, 500 and 1000 nM were tested. 2X working stock for the top 
concentration was prepared in DUB assay buffer and the 2X stocks for the rest of 
the concentrations were prepared by serial dilutions. 5 nM (2X) working stock of 
the enzyme was prepared in DUB assay buffer. 7.5 µL of 2X enzyme and substrate 
working solutions each were dispensed in quadruples. No enzyme blanks for each 
concentration of substrate tested were included in duplicates. The plate was 
centrifuged for 30 seconds to remove any air bubbles and then was read on 
Envision every 5 minutes for 5 hours. The Envision optics settings were as defined 
in the previous section except the measurement height which was set to 11 mm. 
 
The polarisation values were obtained in mP and converted to processed substrate 
at time t, using the following equation, 
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Where 
St: substrate processed till time t,  
S0: initial substrate concentration,  
Pt: polarization value at time t (in mP),  
Pmin: polarization value of 100% processed substrate (50 for free TAMRA),  
Pmax: polarization value of 100 % unprocessed substrate (~200). 
 
The initial rates obtained by a linear fit from 15 to 60 minutes of the reaction, were 
plotted against the substrate concentration used and fitted to enzyme kinetics 
Michaelis-Menten equation using Erithacus GraFit 7.0.2. 
 
2.3.2.4 Selection of enzyme concentration and reaction time 
 
The experiment was performed in a 1536-well, black, medium-binding plate 
(Greiner 782076) at a final assay volume of 6 µL. 200 nM of 2X working stock of 
substrate was prepared in the DUB assay buffer from 100 µM stock in DMSO. 
Different concentrations of enzyme viz. 0, 2.5, 5, 10, 15 and 20 nM were tested. 2X 
working stock for the top concentration was prepared in DUB assay buffer from 
4.697 µM stock and the 2X stocks for the rest of the concentrations were prepared 
by serial dilutions. The experiment was performed in the presence of 1% DMSO 
which will be the concentration of DMSO in final HTS. 3 µL of 2X enzyme and 
substrate working solutions each were dispensed in 12 replicates. The final 
substrate concentration was 100 nM, the recommended concentration by the 
manufacturer for this class of enzymes. The plate was centrifuged for 1 minute to 
remove any air bubbles and then was read on Envision every 10 minutes for 
approximately 8 hours. The Envision optics were configured as defined in the 
previous section. 
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2.3.2.5 Selection of final reaction volume, controls and effect of 
centrifugation 
 
The experiment was performed in a 1536-well, black, medium-binding plate 
(Greiner 782076) and the different final assay volumes that were tested were 4, 5 
and 6 µL. The experiment was performed in the presence of 1% DMSO which is 
the concentration of DMSO in HTS reactions. The different positive controls tested 
were a) minus enzyme b) excess iodoacetamide (10 mM) and c) 50 µM H1, which 
is a dechloro analogue of HBX 41,108 (Colland et al., 2009, de Jong et al., 2012). 
Final assay concentrations for enzyme and substrate were 5 and 100 nM 
respectively. To test these conditions an experiment was designed as shown in the 
plate map in Figure 2.2.  
 
 
Figure 2.2: Plate map for comparing different positive controls.  
Each 1536 plate was prepared as shown above for different volumes and the 
assay performance was compared by comparing three different positive 
controls and negative (+E) control (384 wells per condition). 
 
The plates were either centrifuged or not for 1 min at 179 g (1000 rpm) using 
Beckman Allegra 25R centrifuge with TS-5.1-500 rotor to remove air bubbles and 
then were read on Envision every 18.3 minutes for 6 hours. The settings used for 
the optics on Envision were: measurement height 8.91 mm, number of flashes 10, 
PMT gain 305, second PMT gain 225, G-factor 0.8 and excitation light 60%. 
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2.3.3 HTS 
 
2.3.3.1 Screening at single-concentration and dose response 
 
The primary screening was performed at a single concentration of compound at 
10 µM. Dose response studies were performed with 100 µM compound as the 
typical highest tested concentration followed by ten 1/3 dilutions and hence 1.7 nM 
was typically the lowest tested concentration for each compound. 50 nL of 
compounds dissolved in DMSO at 100x the final assay concentration were 
dispensed in 1536-well plates using Echo liquid handling system. The Echo audits 
each well of the mother plates and calculates the level of hydration of the DMSO 
and the depth of the fluid in the well; this survey is  used to ensure accurate and 
precise nanoliter transfer. The Echo also reports empty wells when the volume in 
the well is not enough or when the compound precipitates into the well and the 
solution is not homogeneous. There is no contact between the ejection mechanism 
and the sample, eliminating tips and hazardous waste and cross-contamination 
issues.  
 
The screening was performed in 1536-well, black, medium-binding plates (Greiner 
782076). In all the plates tested, columns 11 and 12, i.e. 64 wells were used as 
negative control or control 1 and columns 35 and 36 i.e. 64 wells were used as 
positive control or control 2. The assay we used is a fluorescence polarization 
assay. The substrate used was Ubiquitin bound to 5-TAMRA (Ub-FP substrate) 
(Geurink et al., 2012, Tirat et al., 2005). The assay buffer used to prepare enzyme 
and substrate dilutions was 50 mM Tris pH 7.6, 50 mM NaCl, 1 mg/mL (1.626 mM) 
CHAPS, 0.132 mg/mL (2 μM) dBSA, 2 mM DTT, filtered and degassed. All stock 
solutions of buffer components were prepared in 50 mM Tris pH 7.6. DTT should 
always be prepared fresh. 50 nL of 1 M iodoacetamide in DMSO was dispensed in 
positive control wells using Multidrop Combi nL low volume reagent dispenser. 
Enzyme and substrate dispensations were carried out using Multidrop® Combi 
using a small tube metal tip dispensing cassette. 2 µL of 2.5x (12.5 nM) enzyme 
66 
 
was dispensed in all wells. The plates were then incubated at room temperature for 
30 minutes. Following this 3 µL of 1.67x (166.67 nM) substrate was dispensed in 
full plate. Hence the final assay concentrations of enzyme and substrate were 5 nM 
and 100 nM respectively. The reaction was then incubated for 200 mins at room 
temperature (25 ± 2 °C). The plates were stacked or covered during this incubation 
to avoid evaporation. The plates were then read on EnVision™ 2104 multilabel 
reader with laser. The excitation filter used was 531 ± 25 nm (Perkin Elmer 
BODIPY TMR FP 531 bar code 105). The emission filters for the s and p channels 
were 579 ± 25 nm: Perkin Elmer TAMRA FP S-pol 579 bar code 245 and Perkin 
Elmer TAMRA FP P-pol 579 bar code 246 respectively. The mirror module used 
was D555fp/D595 (Perkin Elmer BODIPY TMR FP Dual Enh bar code 682). Other 
settings used for the optics were measurement height 8.91 mm, number of flashes 
10, PMT gain 305, second PMT gain 225, G-factor 0.8 and excitation light 60%. 
 
2.3.3.2 Analysis of data by IDBS activity base and Spotfire-single 
concentration and dose response 
 
The data analysis was carried out using IDBS activity base XE. All plates were bar 
coded and the compound information, which includes concentration and compound 
ID, were uploaded to activity base when the plates were prepared. Upon running 
the HTS the data were acquired on activity base XE and the compound ID and 
concentration data was matched automatically to the data collected depending on 
the plate barcode and well number, hence maintaining highest standards of data 
integrity with minimum manual intervention. 
 
The s and p channel data obtained from envision was uploaded to the IDBS activity 
base XE. All plates from a single batch (60 plates typically) were processed 
together on activity base XE. The expected outcome of the data analysis is percent 
inhibition. The collected data from the parallel and the perpendicular channels were 
used to calculate anisotropy (r) using the equation:  
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Where s is the parallel fluorescence intensity, ex 531 nm, em 579 nm 
p is the perpendicular fluorescence intensity, ex 531 nm, em 579 nm 
G is the G-factor or the grating factor. 
 
FP assays are subject to various types of interference, one of the primary being 
compound auto-fluorescence/quench which can interfere with fluorescence 
polarization-based readout. The total fluorescence intensity (I) of the emission 
beam is used to determine if a compound is auto-fluorescing or auto-quenching, 
and is expressed as: 
 
                              
 
The anisotropy data hence obtained were used to calculate the normalised 
response using the equation: 
 
                                
              
                   
  
 
Where "control1" corresponds to fluorescence polarization measurements in the 
absence of an inhibitor (higher mobility, higher depolarization, lower anisotropy 
values) and 
"control2" corresponds to fluorescence polarization measurements in presence of 
10 mM Iodoacetamide, which is an inhibitor of DUB activity (lower mobility, lower 
depolarization, higher anisotropy values). 
 
The quality control we used for the performance of the assay is Z’ (Zhang et al., 
1999). Z’ accounts for the standard deviation of both the positive and negative 
controls and the assay window. It is calculated as: 
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Where σc+ and σc- are the standard deviations for the positive and negative control 
populations respectively and µc+ and µc- are the robust means of positive and 
negative control populations respectively. 
 
Since Z’ is calculated using the standard deviations and means of control 
populations, it is not affected by the test compounds and hence is a good measure 
of the assay performance when screening a diverse chemical library (Zhang et al., 
1999). We typically use Z’ ≥ 0.4 as the quality control cut-off for the performance of 
an assay. Activity base XE calculates the Z’, signal to background ratio, robust 
means for the negative and positive control populations and the response as 
mentioned in the equation above. Robust statistics are used to diminish the impact 
of outliers, which in our case are the active compounds. The hit cut-off is calculated 
as 
                        
 
Compounds showing response greater than or equal to the hit cut-off were marked 
as hits. 
 
For dose response studies, as mentioned above, 100 µM was the highest 
concentration tested followed by ten 1:3 dilutions. As for single shot studies, for 
analysing the dose response data, the s and p channel data were uploaded to the 
IDBS activity base XE. The FP, normalisation and Z’ calculations were the same as 
described above. The expected outcome of this analysis is pIC50.  
 
The IC50 values are calculated by fitting the normalised data, calculated as 
described above, to a four parameter logistic fit equation: 
   
   
          
   
The equation can be rewritten as: 
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In both the equations above, x is the concentration of the test compound, y is the 
inhibition or normalised response (%), A is the maximum signal, D is the minimum 
signal (background), C is the IC50 and B is the Hill slope. IC50 is the concentration 
of the compound at which it shows half (50%) of the maximum response observed. 
   
Expressing IC50 values in molar units, the pIC50 values are calculated as: 
           
 
    
  
For validating the fit to a four parameter logistic equation the following parameters 
were defined. The threshold above which points were excluded automatically from 
the data analysis was set to 300. The software was allowed to remove a maximum 
of 2 points per curve. At least 8 data points were required to fit a curve. A 
compound was marked inactive if the maximum response was less than 30 %. If all 
observed points were below 50 % (but at least some points above 30 %) response, 
the compound was marked as poorly active. Additionally, the compound was 
labelled poorly active if a) the curve fit failed due to XC50 confidence limit (CL) b) 
the R square was > 0.8 defining a concentration dependent effect, c) the fitted 
pXC50 < 3
rd highest concentration tested. A compound was labelled highly active if 
the minimum observed response was greater than 50%. 
 
For limiting the curve fitting algorithm the minimum response was constrained to be 
between -20 % and 20 % and the maximum response was constrained to be 
between 80 % and 120 %. The hill slope was constrained between 0.5 and 5. 
Lastly, the XC50 95 % confidence limit was set to 10. This meant that curve fit will 
fail QC testing if the ratio of the XC50 upper 95% confidence limit divided by XC50 
lower 95% confidence limit is greater than 10. Finally, despite these settings there 
are always cases of points that fail to fit. These curves were manually checked and 
some outlier points were excluded to obtain curve fits. 
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2.3.3.3 Pattern recognition and correction 
 
For the single concentration data, the patterns in the plates were identified and 
removed (Coma et al., 2009). The smoothing algorithm for pattern correction uses 
a smoothed running median in 2D to calculate a pattern that it is then subtracted 
from the response (Coma et al., 2009). Additionally, the data were corrected for 
region dependent hit rates using a robust algorithm to mark hits (ANALYTICAL 
METHODS COMMITTEE, 1989) using all the samples in a well position (and 
alternatively the surrounding wells) for each well; in this way, the cut-off adapts to 
the inhomogeneities of the average response across the well positions. By using 
this "transverse-cut-off" approach the pattern disappeared. The calculations were 
performed using a C program written to this effect. 
  
2.3.4 Sans DTT assay 
 
The assay and data analysis is exactly the same as described in section 2.3.3 
except that DTT was not included in the assay buffer. Hence the assay buffer used 
was 50 mM Tris pH 7.6, 50 mM NaCl, 1 mg/mL (1.626 mM) CHAPS, 0.132 mg/mL 
(2 μM) dBSA, filtered and degassed. 
 
2.3.5 SOD/Catalase assay 
 
The assay and data analysis is exactly the same as described in section 2.3.3 
except that superoxide dismutase and catalase were added to the assay buffer. 
Hence the assay buffer used was 50 mM Tris pH 7.6, 50 mM NaCl, 1 mg/mL 
(1.626 mM) CHAPS, 0.132 mg/mL (2 μM) dBSA, 10 μg/mL SOD, 500 μg/mL 
catalase, 2 mM DTT, filtered and degassed. 
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2.3.6 L-Cys assay 
 
The assay and data analysis is exactly the same as described in section 2.3.3 
except that DTT was replaced by L-cysteine in the assay buffer. Hence the assay 
buffer used was 50 mM Tris pH 7.6, 50 mM NaCl, 1 mg/mL (1.626 mM) CHAPS, 
0.132 mg/mL (2 μM) dBSA, 2 mM L-Cys, filtered and degassed. 
 
2.3.7 Resazurin assay 
 
The plate preparation was the same as described in section. The assay buffer was 
50mM Hepes, 50mM KCl, pH 7.5. 1 mM stocks of resazurin and resorufin and 1 M 
stock of DTT were prepared in assay buffer. 5 µL of 5 μM resazurin and 2 mM DTT 
in assay buffer was dispensed in full plate except positive control wells (columns 
35 and 36). For positive control 5 µL of 5 μM resorufin and 2 mM DTT in assay 
buffer was dispensed. The plate was then incubated at room temperature for 1 
hour protected from light. The plate was then read on EnVision™ 2104 multilabel 
reader with laser. The excitation and emission filters used were 535 ± 40 nm 
(Perkin Elmer Resorufine/Amplex Red FP 535 bar code 124) and 595 ± 60 nm 
(Perkin Elmer Cy3 595 bar code 229) respectively. The mirror module used was 
D555 (Perkin Elmer Bodipy TMR bar code 405). Other settings used for the optics 
were measurement height 10 mm, number of flashes 1, PMT gain 1 and excitation 
light 1%. High concentration mode was enabled to avoid saturation of optics. 
 
The fluorescence intensity data hence obtained were used to calculate normalised 
response using IDBS activity base XE as described above and the curve fitting and 
pIC50 calculations were done as described above. 
 
2.3.8 hCTSB assay 
 
The assay was carried out in 384 well low volume black plates (Greiner 784076). 
100 nL of compounds dissolved in DMSO at 100x the final assay concentration 
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were dispensed in 384 well plates using Echo liquid handling system. The assay 
buffer was 100 mM sodium acetate, 150 mM NaCl, 5 mM EDTA, 1 mM CHAPS, 40 
µM L-cys, pH 5.5. A stock solution of Cathepsin B (14 μM, obtained from GSK in-
house repository of reagents, expressed and purified in-house) was diluted in 
assay buffer to give a conc. of 150 pM. The substrate used was Z-Phe-Arg-AFC. A 
substrate stock of 20mM (M.W. 710) was prepared in neat DMSO. This was then 
diluted to 50 µM in assay buffer. In 384 well format column 6 (16 wells) was used 
for negative control while column 18 (16 wells) was used for positive control. 5 µL 
of 150 pM CTSB was dispensed to all wells except to column 18. 5 µL of assay 
buffer was dispensed to positive control wells. The plate was then incubated for 30 
minutes at room temperature. Then 5 µL of 50 µM substrate was dispensed to all 
wells. The reaction was incubated at room temperature for 2 hours after which it 
was stopped with 2 µL of 100 µM E64 in 25% DMSO. The plates were then read 
on EnVision™ 2104 multilabel reader with laser. The excitation and emission filters 
used were 380 ± 10 nm (Perkin Elmer Fura2, BFP 380 bar code 112) and 
495 ± 10 nm (Perkin Elmer TRF Emission 495 bar code 276) respectively. The 
mirror module used was D425 (Perkin Elmer Beta-Lactamase bar code 418). Other 
settings used for the optics were measurement height 9.4 mm, number of flashes 
10, PMT gain 271 and excitation light 10%. 
 
The fluorescence intensity data hence obtained were used to calculate normalised 
response using IDBS activity base XE as described above and the curve fitting and 
pIC50 calculations were done as described above. 
 
2.3.9 T. brucei cell culture 
 
2T1 Trypanosoma brucei brucei cells derived from strain s427 were modified to 
integrate the TbrDUB1 gene under the control of a tetracycline operator in the 
ribosomal RNA locus on chromosome 2a (Jones et al., 2014, Alsford and Horn, 
2008) (received from Dr. Boris Rodenko). This allows tetracycline induced 
overexpression of the myc6TbrDUB1 gene product. The selection markers used to 
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maintain this cell line are Hygromycin (2.5 μg/mL) and Phleomycin (0.5 μg/mL). 
The cells were maintained in a continuous culture in T-flasks at 37 °C, 100% 
humidity, 5% CO2 in a Heraeus Cytomat incubator. The cell density was 
maintained below the stationary phase (2x106 cells/mL) by diluting them in fresh 
pre-warmed (to 37 °C) T. brucei complete culture medium. The cells can be 
maintained in exponential growth phase by maintaining the cell count between 
2x105 and 2x106 cells/mL with typically 3 passages per week. Cells were counted 
using either CASY cell counter or disposable hemocytometer.  
 
2.3.10 Overexpression of TbrDUB1 in T. brucei and cell lysis 
 
Overexpression of TbrDUB1 was induced by adding 1 µg/mL tetracycline from a 
1000x stock of tetracycline in 70% ethanol. Samples were taken just before 
screening, and the after another 24 hours which marks the end of screening. 2X107 
cells were pelleted by centrifugation at 800 g, 10 minutes at 4 °C. The cells were 
given a quick wash in PBS. Following this the cells were lysed in 1X SDS loading 
buffer to obtain lysate equivalent to 2x105 cells/µL. 4x106 cell equivalent lysate and 
E. coli positive control whole cell lysate (Abcam ab5395, serves as positive control 
for anti-myc antibody) were loaded on a Biorad mini protean TGX stain free precast 
gel and resolved using a constant voltage of typically 200 V. Following this, the gel 
was imaged in stain-free mode on Biorad ChemidocMP. This gel was then used for 
western transfer using the dry transfer technique with Invitrogen iBlot kit and 
instrument. The transfer time used was 7 minutes. The blot was then incubated 
with 5% fat free milk in PBS at room temperature for at least 1 h, followed by 3 
washes of 5 minutes each with 0.05% PBST. The blot was then incubated with 
1:200 dilution in PBS of anti-myc tag antibody, clone 4A6, alexa fluor® 555 
conjugate for 1 hour at room temperature. This was followed by 4 washes of 5 
minutes each with 0.05% PBST. The western blot was then imaged on Biorad 
ChemidocMP using green epi illumination and 605 ± 50 emission filter. Also, a 
multichannel image of the western blot was taken combining a stain free image of 
74 
 
the blot and alexa 555 signal. This allows us to compare the total protein in a lane, 
across the lanes and acts a loading control.  
 
2.3.11 T. brucei whole cell screening 
 
We tested the effect of all TbrDUB1 hits on the parasite using an ATP based 
viability assay described in (Sykes and Avery, 2009) and used as an orthogonal 
assay in (Pena et al., 2015). The screening was performed in a 1536-well, 
CELLSTAR®, HiBase, tissue culture treated, flat bottom, white microplates (Greiner 
782073) covered with sterile lids (Greiner 656191). The highest compound 
concentration tested was 41.67 µM, followed by ten 1/3 dilutions. 25 nL of 240x 
compound stock in DMSO was dispensed in the plates using Echo liquid handling 
system. As usual, columns 11 and 12 of each plate were used as negative controls 
and columns 35 and 36 as positive controls. The negative control we used was 
cells growing in the absence of any compound. For positive control we used 
complete culture medium without any cells. To set up the screening, the cells were 
diluted to 1000 cells/mL and maintained in presence of selection markers for 72 
hours. In case of induction of overexpression 1 µg/mL tetracycline was also added. 
The cells were further maintained in log-phase of growth (seed at 1x105 cells/mL) 
for at least 24 hours in the absence of selection markers before the screening 
although tetracycline was maintained in the case of induction. At this point a 
sample of cells (pre-screening) was taken to check for TbrDUB1 overexpression as 
described in the previous section. For screening, all reagents dispensations were 
carried out using Multidrop® Combi using a small tube metal tip dispensing 
cassette. 6 µL of fresh complete culture medium were dispensed to positive control 
wells. 6 µL of 50,000 cells/mL (300 cells/well) were dispensed in the plate except to 
positive control wells. The plates were covered with sterile lids and incubated for 
24 hours at 37 °C, 100% humidity, 5% CO2 in a Galaxy R CO2 incubator. The 
parasite load in the wells was determined by measuring the ATP content in each 
well using 4 µL of CellTitre-Glo luminescent cell viability assay reagent. The plate 
was then allowed to incubate at room temperature for 60 minutes to allow the 
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signal to stabilize. The plates were then read on Wallac ViewLux 1430 ultraHTS 
microplate imager. Settings used for the optics were: exposure time 15 s, readout 
speed 10 µs, readout gain 50X, image binning 3X and emission filter 613 ± 55. 
 
The chemiluminescence data hence obtained were used to calculate normalised 
response using IDBS activity base XE as described above and the curve fitting and 
pIC50 calculations were done as described above, except that hill slope was 
constrained between 0.5 and 10 and the threshold to exclude a data point was set 
very high so as to avoid loss of data points. These were manually checked later. 
 
2.3.12 In silico clustering of compounds 
 
For clustering similar compounds, a complete link agglomerative hierarchical 
clustering was performed (Leach and Gillet, 2007). Agglomerative hierarchical 
clustering method is the one that starts by considering each compound a different 
cluster and then merges most similar clusters to form bigger clusters. The 
algorithm continues merging similar clusters together till no pairs of clusters are 
more similar than the defined cut-off. The complete link method of clustering is the 
one in which the similarity between clusters is defined as the minimum similarity 
between pairs of compounds in two different clusters. The similarity between 
compounds was defined by the tanimoto similarity between the fingerprints of 
compounds. The cut-off for tanimoto similarity was defined to be 0.55 to perform 
this clustering. 
 
2.3.13 HepG2 cytotoxicity assay 
 
The assay was carried out in 384 well low volume black plates (Greiner 781091). 
250 nL of compounds dissolved in DMSO at 100x the final assay concentration 
were dispensed in 384 well plates using Echo liquid handling system. Cell culture 
medium was Eagles MEM with L-Glutamine and Earle's Salts, 10% FBS, 1% of 
100X non essential amino acid solution. 100 µM digitoxin in DMSO was used to 
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inhibit growth in positive control wells. Actively growing HepG2 cells were removed 
from a T-175 flask using culture medium (5mL), and made as disperse as possible 
by repeated pipetting. Cell suspension was added to 500 mL culture medium + 1% 
Penicillin + Streptomycin. 25 µL were dispensed into all wells of Greiner black 384-
well plates using a Multidrop. Seeding density should be checked to ensure that 
new monolayers are not more than ~50% confluent at the time of seeding (typically 
3000 cells per well), before completing preparation of plates. Cells are left at 37 °C, 
5% CO2 in a humidified incubator in the presence of compound for 48 hours. ATP 
content in each well was measured using 25 µL of CellTitre-Glo luminescent cell 
viability assay reagent. The plates were centrifuged and then allowed to incubate 
at room temperature for 10 minutes to allow the signal to stabilize. The plates were 
then read on Wallac ViewLux 1430 ultraHTS microplate imager. Settings used for 
the optics were: exposure time 5 s, readout speed 10 µs, readout gain 50X, image 
binning 2X and emission filter 613±55. 
 
The chemiluminescence data hence obtained were used to calculate normalised 
response using IDBS activity base XE as described above and the curve fitting and 
pIC50 calculations were done as described above, except that a) the threshold to 
exclude a data point was set very high so as to avoid loss of data points b) the 
threshold to mark poorly active compounds was set to 60% c) the threshold for 
marking inactives was set to 60% and d) the hill slope was constrained between 
0.5 and 6. 
 
2.3.14 Intra-macrophage L. donovani assay 
 
The assay is described in detail in Peña et al. (Pena et al., 2015) and adapted from 
Rycker et al. (De Rycker et al., 2013). THP-1 cells differentiated to macrophage-
like cells using phorbol 12-myristate 13-acetate (PMA) were used. The cells were 
maintained at 37 °C, 5% CO2 for 24h and cell differentiation was confirmed using 
an optical microscope. After washing, the cells were infected using eGFP LdBOB 
axenic amastigotes at a multiplicity of infection of 10 (i.e. 6 x 106 parasites/mL). 
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After overnight incubation, the remaining parasites were removed  by 3x washes 
with sterile D-PBS. The infected cells were harvested using 0.05% (w/v) trypsin 
and 0.48 mM EDTA for 5 min.  An aliquot was fixed and counted in a CASY cell 
counter. Cells were diluted to a final concentration of 1.6x105 cells/mL in assay 
medium consisting of RPMI (InvitrogenTM), 2% FBS (Gibco), 25 mM sodium 
bicarbonate (InvitrogenTM) and 30 nM of PMA. Compound plates were prepared 
by dispensing 250 nL of compound in DMSO and for a dose response eleven point 
one in three dilutions with highest concentration of 50 µM were tested. The cells 
were plated onto assay plates containing compounds (3000 cells/well, 50 µL) using 
a Multidrop Combi in all columns except the positive control. For positive control, 
Amphotericin B was added to an aliquot of infected cells to a final concentration of 
2 mM and dispensed to the control column using a Multidrop Combi. Plates were 
incubated for 96 h at 37 °C, 5% CO2 and then fixed with 4% (v/v) formaldehyde-
PBS for 30 min at room temperature. After fixation, the wells were washed twice 
with 100 mL PBS using an EL406 multi well plate washer (BioTek), stained with 10 
mg/mL DAPI in PBS with 0.1% (v/v) Triton X-100 for 30 min at room temperature, 
and lastly washed twice with 50 mL PBS. Finally, 50 mL of PBS was added to each 
well and the plates were sealed. The plates were read on a high-content 
microscope (Opera QEHS) using a 20x objective, 3 fields per well. Two exposure 
images were taken for each well using 405 nm and 488 nm laser excitation. 
Automated image analysis was performed with a script developed on AcapellaH 
High Content Imaging and Analysis Software (PerkinElmer). THP-1 cell count, 
average number of amastigotes per macrophage and percent of infected cells were 
calculated for each well. 
 
2.3.15 T. cruzi intracellular imaging assay 
 
The assay is described in detail in Peña et al. (Pena et al., 2015). It has been 
adapted from Alonso-Padilla et al. (Alonso-Padilla et al., 2015) . Briefly, H9c2 cells 
were seeded in T-225 flasks in DMEM-10% FBS for 4 h to allow attachment. Cells 
were then washed once with PBS before infection. T. cruzi trypomastigotes were 
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collected at days 5 to 8 post infection from LLC-MK2 parasite infected cultures by 
centrifuging the culture at 2500 rpm for 10 minutes at room temperature followed 
by allowing the trypomastigotes to swim out for 4 h at 37 °C. These were then 
collected and counted in a CASY Cell Counter. Trypomastigotes, in supplemented 
DMEM, were added to H9c2 cultures in a multiplicity of infection of 1 and incubated 
for 18 h. Cells were washed once with PBS. The infected cells were harvested by 
trypsin treatment. Cells were counted in a CASY Cell Counter using a 150 mm and 
diluted to 5 x 104 cells per mL in supplemented assay DMEM. 50 µL of this cell 
preparation was dispensed per well into 384-well poly-lysine coated assay plates 
using a Multidrop Combi. The plates were incubated at 37 °C, 5% CO2 for 72 h. 
Cultures were then fixed and stained by addition of 50 µL of a solution containing 
8% formaldehyde and 4 µM DRAQ5 DNA dye (BioStatus, UK) per well. Plates 
were incubated for 1h at room temperature and imaged using a Perkin-Elmer 
Opera microscope with 20x air objective (NA 0.4)  using a 635 nm laser excitation 
and a 690/50 emission detection filter for DRAQ5 detection. Five images were 
collected per well for reliable statistical analysis. Automated image analysis was 
performed with a script developed on AcapellaH High Content Imaging and 
Analysis Software (PerkinElmer). Three outputs were reported for each well: (1) 
number of host cells nuclei to determine drug-related cytotoxicity; (2) number of 
amastigotes per cell as infection level measurement; and (3) percentage of 
infected cells per well as a second infection marker. 
 
 
  
 
 
 
Results 
 
  
 
 
 
Chapter 3 Purification of 
TbrDUB1 and assay 
development 
 
 
Abstract  
TbrDUB1 is a validated target in T. brucei. This chapter summarises the 
purification and characterisation of recombinantly expressed TbrDUB1 and the 
development and validation of a reproducible and robust assay for screening the 
GSK compound collection to identify inhibitors of TbrDUB1. Screening a small set 
of 9838 compounds that sample HTS library gave a hit rate of 0.26% with a 
confirmation rate of 69%. 
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3.1 Protein expression and purification 
 
3.1.1 Expression of TbrDUB1 in insect cells (Sf9) 
 
After several unsuccessful attempts to express soluble codon-optimized TbrDUB1 
in E. coli, we utilized insect cells (Sf9) to express recombinant TbrDUB1, as the 
feasibility of this system to express soluble recombinant TbrDUB1 was previously 
demonstrated (Dr. Boris Rodenko, oral communication). The full-length TbrDUB1 
gene was cloned in the pFastBac-Htb vector, with N-terminal His-tag (the construct 
was received from Dr. Boris Rodenko). This construct was used to generate the 
bacmid by transforming competent DH10Bac E. coli cells. The detailed method is 
described in section 2.3.1.1. Following this, the bacmid was used to transfect 
insect cells (Sf9) maintained in a logarithmic growth phase, to obtain the first 
generation of baculovirus- the P0, in replicates. These P0 baculovirus were used to 
infect a larger batch of Sf9 cells to amplify the amount of the virus (P1 generation). 
These P1 stocks were then tested in multiplicity of infection (MOI) studies to 
identify the best conditions for the expression of the protein. For this, Sf9 cells were 
infected with two different P1 baculovirus stocks (named Bac1 and NKIBac) each 
at a dilution of 1/500 and 1/1000, and the levels of protein expression were 
analysed at 24, 48 and 72 h post-infection (PI) by western blotting. Highest protein 
expression level was observed using 1/1000 dilution of NKIBac 48h PI (Figure 
3.1).  
 
3.1.2 Purification of TbrDUB1 
 
Using the optimised expression conditions, TbrDUB1 was produced in large scale 
cultures (5 L) of Sf9 cells and purified via immobilized metal ion affinity 
chromatography (IMAC) followed by size exclusion chromatography (SEC). 
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Figure 3.1: Determination of optimum conditions for expression of 
TbrDUB1. 
Different concentrations of two P1 stocks were checked for expression of 
protein at indicated time points. Shown here is an immunoblot probed with anti-
his antibodies. Lanes are named as Bacmid name_dilution_time post-infection. 
NKIBac at 1/1000 dilution at 48 h PI showed highest expression levels of 
TbrDUB1 (lane 2). The molecular weight is expressed in kDa. 
 
Briefly, insect cell pellet was resuspended in lysis buffer and cell lysis was carried 
out by sonication. Following removal of cell debris  by ultracentrifugation, the 
supernatant was subjected to affinity purification using a Ni2+ sepharose IMAC 
column coupled to a FPLC system (GE AKTA pure). A shallow linear gradient 
followed by a step gradient of imidazole was used to elute the bound proteins 
(Figure 3.2(A)), and 1 mL fractions were collected in 96 well plates. The collected 
gradient fractions were then analysed by SDS-PAGE and western blotting using 
anti-his antibodies to identify TbrDUB1-containing fractions and assess their purity. 
As seen in Figure 3.2(B), several fractions showed a band at the expected 
molecular weight of 66 kDa. and were of higher relative purity compared to crude 
cell lysate (lane 1 in Figure 3.2(B)). In order to increase the purity of TbrDUB1 the 
fractions were pooled and further resolved using SEC. 
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Figure 3.2 Affinity purification of TbrDUB1.  
(A) The chromatogram for the affinity purification. Shown is the UV280 
chromatogram of the eluted proteins (blue) and the gradient of the elution 
buffer containing imidazole (green). 1 mL fractions in four 96 well plates were 
collected. Each fraction is named as plate number followed by well number. 
For example, first well of the first plate is 1A1. The fractions are shown in red. 
(B) SDS-PAGE gel and western blot of selected fractions, as indicated above 
respective lanes, obtained after affinity purification. Fractions showing an 
intense band at around 66 kDa were pooled and subjected to size exclusion 
chromatography. Molecular weight is expressed in kDa. 
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The pooled fractions were concentrated using a regenerated cellulose membrane 
with 50 kDa. cut-off (Millipore product code: UFC905024), by centrifugation. For 
SEC, a column with cross-linked agarose and dextran (GE HiLoad 16/600 
Superdex 200 pg column) coupled to a FPLC system (GE AKTA pure) was used 
with a flow rate of 0.5 mL/min (15 cm/h). An isocratic 2 column volume elution was 
used. Shown in Figure 3.3(A) is the UV280 chromatogram for the SEC run of two 
different batches. The chromatograms show that the run is reproducible. A western 
blot analysis (Figure 3.3(B)) showed the TbrDUB1 band at the expected molecular 
weight with higher purity than those obtained after affinity purification. Finally, SEC 
fractions containing TbrDUB1 were combined (Figure 3.3(C)) and yielded a total of 
10.85 mg TbrDUB1 at a concentration of 310 µg/mL (4.697 µM) and a purity of 
75%, from five litre cell culture i.e. ~2 mg  TbrDUB1 per litre of cell culture. 
  
In summary, protein expression in Sf9 cells and the described two-step purification 
yielded a sufficient quantity of high-purity TbrDUB1 for the development of a 
screening assay and HTS purposes.   
 
3.2 TbrDUB1 sequence homology 
 
The sequence of TbrDUB1 in presented in Figure 3.4. TbrDUB1 is identified in 
Uniprot database with id Q386W6 and in TriTrypDB (a Kinetoplastid genomics 
resource) with id number Tb927.11.1930. A blast was performed to identify the 
closest orthologues in T. cruzi, Leishmania spp. and humans. The TbrDUB1 shows 
48%, 38.6% and 22.1% identity with the closest orthologues in T. cruzi, L. infantum 
and humans respectively. T. brucei, T. cruzi and Leishmania have similar genomic 
sequence and biology (El-Sayed et al., 2005). It has been shown that compounds 
targeting a conserved target could be active against all three parasites (Khare et 
al., 2016). Since the target DUB shows higher similarity across these species 
compared to the closest human orthologue, it is likely that the inhibitors identified 
against one species would be efficacious against the others as well. 
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Figure 3.3: Size exclusion chromatography to purify TbrDUB1.  
(A) UV280 chromatogram of eluted proteins during size exclusion 
chromatography. Shown above are the chromatograms from 2 different runs, 
which show high reproducibility. The injection and elution phase for the first run 
are shown in blue and red respectively while for the second run are shown in 
purple and black respectively. (B) SDS-PAGE and western blot of fractions 
representative of different peaks. A strong signal with anti-his antibodies at the 
expected molecular weight indicates purification of TbrDUB1. The percent 
purity improved after gel filtration. Fractions showing TbrDUB1 were pooled 
and the final preparation of TbrDUB1 shows high purity as seen in a 
coomassie stained gel (C). Molecular weight is expressed in kDa. 
 
87 
 
 
 
Figure 3.4: Multiple sequence alignment of TbrDUB1 orthologues of T. 
cruzi, L. infantum and Homo sapiens.  
TbrDUB1 shows 48%, 38.6% and 22.1% identity with the closest orthologues 
in T. cruzi, L. infantum and humans, respectively 
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3.3 Enzyme characterisation and assay development for HTS 
 
Assay development is an iterative process that can be very challenging as 
numerous variables are involved. It typically includes optimisation of the assay 
buffer, the plate reader optics, the enzyme and substrate concentration, the time of 
reaction, enzyme kinetics parameters, reaction volume, controls etc. The 
biochemical assay we optimised for the HTS is a fluorescence polarization (FP) 
assay. In FP assays the excitation light is plane polarized. Polarization of the 
emitted light depends on the fluorophore lifetime (τ) and the rotational relaxation 
time (µ). µ is the time an excited molecule takes to rotate through an angle of 68.5° 
and is defined by the equation 
 
  
   
  
 
   
Where η is viscosity of the solvent, V is the molar volume, R is the universal gas 
constant and T is the temperature. FP (expressed in mP) is proportional to the 
rotation relaxation time which in turn is proportional to the size/volume of the 
fluorescent molecule. A large molecule rotates slow and therefore emits light in the 
same plane as the excitation light, yielding a high FP value. In contrast, a small 
molecule rotates fast and emits depolarized light (in a different plane from the 
excitation light), leading to a low FP value (Figure 3.5(B)). The FP readout is 
independent of the concentration of the fluorophore. 
 
The DUB substrate Ub-FP is a 5-carboxytetramethylrhodamine (5-TAMRA) 
modified Lys-Gly sequence that is linked to a ubiquitin via a native isopeptide bond 
with the lysine side-chain (5 -TAMRA-Lys(Ub)-Gly-OH) (Geurink et al., 2012, Tirat 
et al., 2005). An active DUB cleaves the isopeptide linkage to release 5-TAMRA 
which is significantly smaller than the substrate. At the time of setting up the assay, 
this was the only available DUB substrate with an isopeptide linkage. Since 
naturally DUBs cleave isopeptide linkages, this substrate has a higher 
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physiological relevance than others where the DUBs have to cleave a peptide 
linkage. The next sections describe the optimisations of assay conditions that were 
performed in order to obtain a miniaturised, robust and reproducible high-
throughput DUB activity assay. 
 
 
Figure 3.5 Assay principle and different assay parameters that need to be 
optimised.  
(A) Structure of Ub-FP substrate. The substrate is 5-TAMRA modified Lys-Gly 
sequence that is linked to a ubiquitin via a native isopeptide bond with the 
lysine side-chain. An active DUB will cleave the isopeptide bond and release 
free 5-TAMRA. Since 5-TAMRA is smaller in size compared to the substrate, it 
depolarizes the light more (B) and this difference can be measured to 
determine the activity. (C) Overview of parameters that were optimised during 
the development of the DUB activity assay 
 
3.3.1 Buffer optimisation 
 
For any assay it is critical to optimise the reaction buffer to ensure optimal enzyme 
activity. For a high throughput DUB assay, the assay buffer should contain a 
buffering agent, a reducing agent, an electrolyte, a detergent and a carrier protein. 
The buffering agent is required to maintain the pH of the reaction mix, the reducing 
agent to maintain the DUB in a reduced state and the electrolyte, detergent and the 
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carrier protein to minimize variability caused by interactions with the tubing and 
plastic material that is used for the screening. 
 
For an optimal composition of the TbrDUB1 activity assay buffer, we first 
determined the components that are essential for enzyme activity, which were 
found to be the detergent CHAPS with DTT as reducing agent (data not shown). 
We then tested multiple buffer additives at different concentrations (Figure 2.1) in 
order to obtain a large enough assay window for a robust assay. Assay window is 
the difference between the signal of the positive and negative controls. 
 
To evaluate the effect of additives, enzyme activity was normalised to the activity 
observed in the assay buffer recommended by the commercial suppliers of the 
substrate (50 mM Tris pH 7.6, 100 mM NaCl, 1 mg/mL (1.6 mM) CHAPS, 0.5 
mg/mL (3.33 µM) bovine gamma globulin (BGG), 2 mM DTT). This gave us the 
percent remaining activity. The results are presented in Figure 3.6. EDTA had no 
effect on enzyme activity. 2 µM heat-denatured BSA (dBSA) performed as well as 
3.33 µM BGG. Thus BGG was replaced with dBSA because BSA is cheaper than 
bovine gamma globulin and more importantly dBSA overcomes the compounds 
masking effects of BSA (Pena and Dominguez, 2010).  None of the detergents that 
were tested gave a significantly better performance than CHAPS. The optimum 
concentration of DTT is 2-4 mM and we decided to use 2 mM in the final assay 
buffer. It is important to include an electrolyte in the assay buffer to reduce the 
interaction with plastic material of the assay plate. Since reducing the 
concentration of NaCl did not affect enzyme activity, its concentration was halved 
to 50 mM.  
 
The final DUB assay buffer is thus composed of 50 mM Tris pH 7.6, 50 mM NaCl, 
1 mg/mL (1.6 mM) CHAPS, 0.132 mg/mL (2 µM) heat denatured BSA and 2 mM 
DTT. To prevent interferences with the assay caused by particles or air micro-
bubbles, the buffer is filtered and degassed prior to use. 
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Figure 3.6: Buffer additive screen.  
Different components of the assay buffer were tested to determine the 
conditions that yield a good assay window. (A) EDTA has no effect on the 
enzyme activity and dBSA at 2 µM performs as well as BGG. (B), (C) and (D) 
Pluronic acid, CHAPS, TritonX-100, Tween-20 and Tween-80 all give 80 to 
100 % remaining activity at certain concentrations. (E) The optimum 
concentration of DTT is in the range of 2-4 mM. 
 
3.3.2 Product standard curve 
 
A very important factor for the successful performance of an assay in the HTS is 
the plate reader. Several high throughput capable plate readers are available like 
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the EnVision™ 2104 MultiLabel Reader (henceforth called EnVision), ViewLux, 
Spectramax, Analyst GT etc. Different readers are better suited for different assay 
formats. We used the EnVision plate reader as it had shown robust performance in 
FP-based assays in the past. As already mentioned, the DUB assay is a FP assay 
that is based on the fact that cleaved and uncleaved fluorophore-labelled DUB 
substrate emit light differently when excited by plane polarized light. 
 
FP values (in mP) are determined from measurements of fluorescence signal in the 
planes parallel and perpendicular to the excitation plane (known as s and p 
channel signals), using the equation 
  
                                
 
where s is the Parallel fluorescence intensity, ex 531 nm, em 579 nm 
p is the perpendicular fluorescence intensity, ex 531 nm, em 579 nm 
G is the G-factor or the grating factor 
 
To consider a plate reader ready for assay readout, it is important to optimise the 
settings of the optics so as to obtain a linear product standard curve between the 
maximum and minimum expected signal in the assay. For a FP assay, the 
EnVision optics need to be optimised for the G-Factor, measurement height, 
excitation light %, the number of flashes per well and detector (PMT) gain. Since 
there are two channels, there are two respective detectors (PMTs). An instrument 
can have different sensitivities for the two channels (s and p). The G-factor is used 
to correct for the bias in polarization values caused by differences in instruments 
and assay conditions. For the EnVision plate readers, the G-factor was determined 
following the manufacturer’s instructions. To calculate the G-factor, the target mP 
values for 5-TAMRA and the substrate (Ub-FP) used were 50 and 200 mP, 
respectively. Optics settings were optimised for two EnVision plate readers, with 
EnVision 1 as the main reader for the HTS and EnVision 2 as the backup reader. 
Iterative readouts were obtained while varying the settings of the optics to obtain 
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readouts as close as possible to the target mP for the substrate and product. 
Optimal optics settings for EnVision 1 were a measurement height of 8.91 mm, 10 
light flashes, a PMT gain of 305, a second PMT gain of 225, a G-factor of 0.8 and 
60% excitation light. The same settings were used for EnVision 2 except for the 
measurement height which is 11 mm and a G-factor of 1. 
 
With the optics settings in place, we then tested if the two readers for the linearity 
of the product standard curve. As shown in Figure 3.7, the two readers gave a 
similar product standard curve and identical slopes using linear regression, 
confirming that the readers can be considered optically identical.  
 
 
 
Figure 3.7: Product standard curve.  
Two EnVision readers were prepared to read the plates for the HTS. EnVision 
1 was used as the reader during HTS and Envision 2 served as a backup 
reader. Both the readers have identical optics settings and gave a similar 
standard curve slopes. (P: product, S: substrate) 
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3.3.3 Determination of kinetic parameters 
 
To characterize an enzyme for an activity assay it is very important to determine 
the Michaelis-Menten kinetics of the enzyme. To determine the Michaelis-Menten 
kinetics for TbrDUB1, we tested varying concentrations of the substrate (1, 5, 10, 
50, 100, 500 and 1000 nM) at an enzyme concentration of 2.5 nM. The mP values 
obtained were converted to processed substrate at time t as described in section 
2.3.2.4. Since the first 15 minutes of reaction showed large variations, the initial 
rates were obtained by a performing linear fit of remaining substrate concentration 
from 15 to 60 minutes. The initial rates thus obtained were plotted against the 
tested substrate concentrations and fitted to Michaelis-Menten enzyme kinetics 
using Erithacus GraFit 7.0.2 software. The calculated values of Vmax and the KM 
from this fit are 6.2 ± 0.4 nM.min-1 and 1373 ± 156 nM, respectively (Figure 3.8). 
Considering that we just begin to see a plateau of the rate of reaction (V) at the 
highest tested substrate concentration, it is clear that a more precise estimation of 
these constants requires more data points at higher substrate concentrations than 
those tested. Fluorescence polarization assays are very attractive for HTS for 
many reasons but show some limitations too. In our assay, the use of very high 
concentrations of substrate in kinetic studies  is hampered by the fact that the 
resulting polarization value of reaction mixtures is dominated by the anisotropy of 
the substrate. As shown in Figure 3.7, a high substrate to product ratio in the 
reaction mix gives a read out of around 200 mP and thus gives a false impression 
that the reaction did not progress. Despite this limitation, the accuracy of the 
resulting kinetic parameters was deemed sufficient for the purpose of adjusting the 
sensitivity of the assay to different types of inhibitors. The final substrate 
concentration chosen for the assay was 100 nM which is around 0.1 x the 
observed KM. At this concentration of substrate our screen will have higher 
sensitivity towards competitive and noncompetitive inhibitors. The lower sensitivity 
towards uncompetitive inhibitors was considered a worthy sacrifice in context of 
high cost of the substrate and the limitations of the readout technology.    
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Figure 3.8: Michaelis-Menten kinetics of TbrDUB1.  
2.5 nM TbrDUB1 was used to process different substrate concentrations at 
room temperature and the respective rate of reactions were obtained by 
calculating substrate processed at time t from the mP values. The rates of 
these reactions were plotted against the respective substrate concentrations. 
The calculated approximate values of Vmax and the KM are 6.2 nM.min
-1 and 
1373 nM, respectively. 
 
3.3.4 Selection of enzyme concentration and reaction time 
 
For developing a robust assay, it is essential to determine the optimum enzyme 
concentration (Eopt) and the reaction time (treac) while staying in the steady state of 
enzyme kinetics. These two factors are typically inversely related i.e. an increase in 
the enzyme concentration allows for a reduction of the reaction time. To find the 
optimum TbrDUB1 concentration and time of reaction, that ensure reaction linearity 
and a good assay window, we tested different enzyme concentrations and 
monitored the enzyme activity over time up to 500 min post reaction start. A 
substrate concentration of 100 nM was used for these experiments, as high 
substrate concentration (1 µM) interfered with the assay and resulted in an 
observed small assay window (not shown). As shown in Figure 3.9(A, B), different 
enzyme concentrations yielded different initial rates of reaction with assay windows 
between 80 and 100 mP over time. Theoretically, the maximum observable window 
is 150 mPs sine 5-TAMRA and Ub-FP substrate yield 50 and 200 mP, respectively.  
Additionally, it was observed that the plot of rate of reaction (V) vs. enzyme 
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concentration is not linear at concentrations higher than 10 nM. Therefore, to 
ensure steady state kinetics, a final assay concentration of 5 nM enzyme was 
chosen with a reaction time of 2 h, yielding an assay window of 80 mP. Depending 
on Z’ values (Figure 3.9(C)) the time of reaction can be increased  to 200 minutes 
as the reaction is still in the linear phase at this time point. 
 
 
Figure 3.9: Selection of Eopt and treac.  
(A), (B) and (C) - Different enzyme concentrations were checked for linearity of 
initial rates and assay window for up to 500 minutes. Also, the Z’ was 
calculated at each time point (D).   
 
3.3.5 Selection of final reaction volume, controls and the effect of 
centrifugation 
 
The last steps of assay development were to determine robust controls, the final 
assay volume and to test if centrifugation has a positive effect on the assay 
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performance through removal of air bubbles. The negative control or control 1 is 
the reaction in the absence of compounds and hence does not require 
optimisation. However, for the positive control, multiple options can be considered 
to achieve full inhibition of the reaction. We compared three different positive 
controls, a) omitting the enzyme, b) the promiscuous enzyme inhibitor 
iodoacetamide, a cysteine-alkylating agent and c) a pan-DUB inhibitor H1. H1 is a 
dechloro analogue of HBX 41,108- a USP7 inhibitor (compound 17 in Table 1.2, 
(Colland et al., 2009, de Jong et al., 2012)). Reactions for each positive control 
were set up in a final reaction volume of 4, 5 and 6 µL in 1536-well plates in 
duplicate, with one plate being centrifuged while the other was not. Reactions were 
allowed to proceed for 6 hours and the signals were monitored at intervals of 18.3 
min in order to determine the Z’ values over time. 
 
As can be seen in Figure 3.10(A), Z’ values in all plates increased over time, 
owing to an increase of assay window, and reached a maximum at 200 min, a time 
point at which the reaction is still in the linear phase (see Figure 3.9, section 3.3.4) 
This prompted us to change the end point of the assay from 120 min (section 
3.3.4) to 200 min. Amongst the positive controls tested, iodoacetamide gave the 
best Z’ values at 200 min, which is explained by the larger assay window and lower 
coefficient of variation compared to the other controls (Figure 3.10 B-D). Hence, 
we decided to use 10 mM iodoacetamide as the positive control. Regarding the 
reaction volume, a general trend of higher Z’ values in 6 µL reactions was 
observed (in the different controls) compared to reactions in smaller volumes. For 
iodoacetamide, the reaction volume of 5 µL yields a Z’ > 0.52, which is increased 
by ~0.4 in 6-µL reactions (Figure 3.10 B).  Considering that a total of 
approximately two million wells are tested in the HTS, a 1 µL increase in reaction 
volume significantly increases the total amount of enzyme and substrate needed. 
To balance reagent costs and assay robustness, we decided to use a final reaction 
volume of 5 µL. Similarly, even though centrifugation slightly improves the assay 
performance, the gain in robustness does not justify the impact on the logistics of 
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the HTS, considering that approximately 1200 plates are tested. We therefore did 
not include the centrifugation step in the final assay. 
 
 
Figure 3.10: Selection of reaction volume and positive control and testing 
the effect of centrifugation.  
(A) The Z’ trend over time. The Z’ (B), assay window (C) and coefficient of 
variation (D) for each control at t = 200 mins. Iodoacetamide shows a larger 
assay window and lower coefficient of variation, leading to higher Z’ values, 
compared to the other two controls. IA: iodoacetamide; H1: specific DUB 
inhibitor; -E: reaction without enzyme. 
 
In conclusion, we successfully set up a robust FP-based DUB activity assay in a 
1536-well plate format, using a final assay volume of 5 µL with 5 nM TbrDUB1 and 
100 nM substrate, and a reaction time of 200 min. After the test compounds and 
iodoacetamide have been dispensed (assay ready plate) the assay protocol per se 
has just two additions and makes it easy to achieve a high throughput. Typical Z’ 
range for this assay is 0.55-0.6. Iodoacetamide serves as positive control. Lastly, 
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for the HTS, a 30-min preincubation of enzyme with compounds was added to the 
assay protocol to allow for detection of slow-binding compounds.   
 
3.3.6 Assay automation 
 
To run the HTS in a semi-automated manner, we utilized an in-house assembled 
platform consisting of an Agilent direct drive robot arm, several Thermo Electron 
MultiDrop® Combi dispensers and plate racks for holding stacked plates. The 
platform was controlled by Agilent VWorks automation control software. The 
Agilent direct drive robot arm works by defining the coordinates of each location 
within a 3D grid. The robotic arm was used to move each plate from a stack of 
assay ready plates to the first MultiDrop Combi dispenser which adds 2 µL of 
enzyme solution to the plate. Following this, the robotic arm moves the plate to a 
rack for a 30-min incubation of compounds and enzyme. Meanwhile, enzyme 
dispensation continues in more plates, each separated by 3 min, which is the time 
it takes to read each plate on the EnVision. This ensured that each plate has the 
exact same incubation time of enzyme and compounds and when read at the end 
of the reaction. After 30 min of preincubation, the plate is moved to the second 
Multidrop Combi where 3 µL of substrate solution is dispensed and the plate is 
stacked in a rack where it is incubated for 200 min, protected from light. At the end, 
a restacking step is required to put the first plate at the bottom in order to be read 
first by the EnVision plate reader (Figure 3.11(A, B)). 
  
Each plate tested contains two columns (64 wells) for each control, columns 11, 12 
for the negative control and columns 35 and 36 for the positive control 
iodoacetamide (Figure 3.11(C)). With the assay development and automation 
phases complete, the next step is to test the robustness of the assay in the 
presence of the compounds. 
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Figure 3.11: The process workflow and the final assay design.  
(A) The series of working steps on a typical screening day. Plates pre-
dispensed with compounds were tested in batches of 60 (IA: Iodoacetamide). 
(B) The assay protocol. (C) The plate design for the HTS. In a 1536-well plate, 
columns 11 and 12 (a total of 64 wells) serve for negative control (control 1) 
while columns 35 and 36 contain iodoacetamide as positive control (control 2).  
 
3.4 Assay validation 
 
3.4.1 Robustness set 
 
To consider an assay ready for HTS, it is crucial to check how robustly the assay 
performs when exposed to the organic load of compounds in DMSO. For this, the 
normal practice at GSK is to test the assay against a set of 1408 compounds (1 x 
1536-well plate) in duplicate. This set is a subset of the validation set (next section) 
and the full HTS collection, and consists of compounds with a broad range of 
chemical properties. While relatively small, this set allows for identification of major 
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problems in the assay which then can be revisited and optimised. The main 
requirement for passing the robustness test is a Z' > 0.4 in each replicate. 
Additional information that is obtained from testing the robustness set is the mean 
SD of the controls, hit rate, response cut-off for marking hits, correlation coefficient, 
outliers etc. We coupled the robustness test to the test of reagent stability, as in a 
HTS scenario, approx. 60 plates are dispensed over a period of 3 h at room 
temperature. For this, we interspersed the robustness set plates with several plates 
containing the DUB inhibitor H1 in concentrations ranging from 0-100 µM in 1:3 
serial dilutions (dose response plates). Dispensation of these plates was spread 
over a period of ~3 h to simulate the timing during the HTS. In addition to the 
stability of the reagents, the dose response plates of H1 further allow us to assess 
the sensitivity and the reproducibility of the assay. 
 
As shown in Figure 3.12(A), the H1 dose-response tests resulted in reproducible  
IC50 values with an average of 8.8 x 10
-7 ± 4.8 x 10-8 M (pIC50 = 6.1). Robust 
statistics are often used in HTS scenario, wherein outliers are not included when 
calculating the Z’ and coefficient of variation. Despite a relatively low signal-to-
background ratio in all tested plates (1.97 ± 0.10), a good average robust Z’ value 
of 0.6 ± 0.03 was obtained, demonstrating assay robustness (Figure 3.12(B)). 
Importantly, the Z’ value did not decrease over time, indicating that the reagents 
are stable at RT for at least 3 hours, and are therefore suitable for the HTS. 
 
Figure 3.12: Assay performance during robustness test. 
(A) H1 dose response curves (n = 24, 8 plates with 3 replicates per plate) were 
reproducible and gave an average IC50 value of 8.8 x10
-7 ± 4.8 x10-8 M. (B) 
The Z’ value and signal-to-background ratio (S/B) are stable over time and 
indicate a robust assay. 
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As seen in Figure 3.13, only two of the tested compounds showed robust activity 
against TbrDUB1. Compounds are considered as robustly active when the 
response is greater than three times the SD of the mean response of the negative 
control. The small number of actives indicates that either the assay is not sensitive 
to detecting the inhibitors against TbrDUB1 or that the assay is not prone to high 
hit rate. Given the sensitivity to H1, as seen in the H1 dose response in Figure 
3.12(A), the latter might be the case. However, with Z’ > 0.4  the assay passed the 
robustness test and is therefore ready to be tested more extensively on a larger 
compound set (validation set) with respect to reproducibility, hit rate, false positive 
and false negative rates. 
 
 
Figure 3.13: Replicate response correlation for the robustness set. 
Robustness set was tested in duplicate. The assay performance was robust 
and gave only 2 robust hits. 
 
3.4.2 Validation set 
 
The validation set consists of 9838 diverse compounds (7 x 1536-well plates) that 
are representative of the full screening collection, and serves to validate the assay 
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and test its statistical quality before embarking on the HTS. For this, the set is 
tested in triplicate on at least two different days to account for potential day-to-day 
assay variability. The stability and separation of controls (Z’), reproducibility of hits 
and number of outliers are checked. Replicates with less than 80 % of plates 
having acceptable Z’ values (> 0.4) or replicates with many extreme errors are 
causes of concern and indicate the requirement for further assay optimisation.  
 
For the TbrDUB1 assay, the validation replicates were run on two days, one 
replicate on day 1 and two replicates on day 2. The Z’ values were similar in all 
plates of the replicates and above the quality control limit of 0.4, (Figure 3.14) 
indicating a good separation of the controls. 
 
 
Figure 3.14: Assay performance during validation set screening. 
The robust Z’ and robust signal-to-background ratio are similar on the 2 days. 
The Z’ never falls below the quality control limit of 0.4 which indicates that the 
assay is robust.  
 
Furthermore, the replicates showed a strong correlation of response (Figure 3.15). 
The statistical parameters from the analysis of the replicates are presented in 
Table 3.1. As mentioned before, the cut-off for marking robustly active compounds 
is determined as 3x SD of the mean response of the negative control and was 
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24.5 % in the validation set. We obtained a hit rate of 0.26 % with a high predicted 
(for the HTS) confirmation rate of around 69 %. This implies that for a HTS of 
approximately 1.7 million compounds we should expect approximately 4000 hits. 
The false positive and the false negative rates of 0.05 % and 3.51 % are not very 
high. The extreme false positive rate is near zero, confirming the assay’s 
reproducibility. The extreme false negative rate (EFNR) was high (5.26 %) in one 
replicate. However, the other two replicates did not contain any extreme false 
negatives, leading to an acceptable average EFNR of 1.75 %.   
 
In conclusion, the TbrDUB1 assay passed the assay validation and can be 
considered ready for the HTS campaign which is described in the following 
chapter. 
 
 
Figure 3.15: Replicate response correlation of the three copies of the 
validation set.  
The response of each replicate is represented on a different axis, showing 
good correlation. EFN: Extreme false negative, FP: False positive, TA: True 
active, (i): No flag.  
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Table 3.1: Validation set statistical parameters. 
 
Descriptor Name  Descriptor Rep_1 Rep_2 Rep_3 
Avera
ges 
Val. 
Indexes 
Number of data points  ni 9838 9838 9838 
  
Number of considered 
triplets 
 nx3 
    
9838 
Estimated Robust mean  r mean 2.3397 1.391 1.7628 
  
Estimated Robust Standard 
Deviation (SD) 
 r sd 7.2412 7.7211 7.7514 7.57 
 
Cut Off 3 x SD  cut-off 24.06 24.55 25.02 24.54 
 
Robust Average Range (%)  robAR 
    
12.29 
Inter Class Coefficient (ICC)  ICC 
    
0.15 
Number of False Positives  FP 8 2 6 
  
Number of False Negatives  FN 1 0 1 
  
Number of Extreme False 
Positives 
 EFP 0 0 1 
  
Number of Extreme False 
Negatives 
 EFN 1 0 0 
  
Number of Hits  nHits 27 27 23 
  
Number of Triplicated Hits  nx3Hits 27 27 23 
  
Number of Statistical Actives  TA 
    
19 
Number of Statistical 
Inactives 
 TI 
    
9819 
Statistical Active Rate (%)  TAR (%) 
    
0.19 
Predicted Confirmation Rate 
(%) 
 PCR (%) 66.67 70.37 69.57 68.87 
 
Hit Rate (%)  HR (%) 0.27 0.27 0.23 0.26 
 
False Positive Rate (%)  FPR (%) 0.08 0.02 0.06 0.05 
 
False Negative Rate (%)  FNR (%) 5.26 0 5.26 3.51 
 
Extreme False Positive Rate 
(%) 
 EFPR (%) 0 0 0.01 0 
 
Extreme False Negative 
Rate (%) 
 EFNR (%) 5.26 0 0 1.75 
 
  
 
 
 
Chapter 4 Hit identification  
 
 
Abstract  
In this chapter, we present the results from the HTS of the GSK collection of 
approximately 1.7 million compounds against TbrDUB1 using a FP assay. The 
primary screen was performed at a 10 µM compound concentration. 9405 hits were 
identified and were re-tested in duplicate at the same concentration, which yielded 
a total of 2020 confirmed, robustly active compounds. Their potencies and 
physicochemical properties are presented. 
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4.1 High throughput screening 
 
As highlighted in the introduction, one of the proven approaches in drug discovery 
is to screen a chemical library against a target of interest. The chances of 
identifying tractable hits increase when using libraries of structurally diverse 
compounds that sample the chemical space, which in its entirety is too large to 
manage. 
 
The GSK screening library is a dynamic, high-quality collection of around 1.7 
million compounds that has been enriched in structurally diverse drug-like 
molecules over many years. More than 90 % of compounds have a purity of 
> 90 % at the time of incorporation, with the remaining ~10 % of compounds being 
> 80 % pure.  To identify inhibitors of TbrDUB1, we screened the full GSK library 
using a FP-based DUB activity assay that we developed and validated (Chapter 3). 
The primary screen was performed at a final compound concentration of 10 µM, 
according to the assay protocol described in section 2.3.3.1. Briefly, compound 
stocks in DMSO were dispensed in 1536-well plates using an automated Echo 
liquid handling system. Following dispensation of TbrDUB1 (5 nM final 
concentration), the enzyme and compounds were incubated for 30 min before 
starting the reaction by adding the 5-TAMRA-labelled ubiquitin substrate (100 nM 
final concentration). After a reaction time of 200 min, fluorescent signal was 
measured using an EnVision plate reader, and data analysis was performed with 
ActivityBase XE software (see section 2.3.3.2 for details). In each plate, columns 
11 and 12 were used for the negative control, i.e. the uninhibited reaction, while 
columns 35 and 36 contained the positive control iodoacetamide which inhibits the 
enzyme through cysteine alkylation. 
 
A total of 1,893,888 wells in 1233 plates were tested. We screened a total of 
1,668,637 unique compounds. The HTS was carried out in a semi-automated 
manner (section 3.3.6). The average robust Z’ value for all valid plates was 0.57 
with a SD of 0.03 (Figure 4.1(B)). Only seven plates did not pass the quality 
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(B) (A) 
control criterion of a Z’ > 0.4, resulting in a very low failure rate of 0.57 %. 
However, one plate with a Z’ of 0.39 was included in the data analysis, as it had 
only five hits that were easily re-tested in the confirmation step. 
 
 
 
 
Figure 4.1: HTS chronogram and Z’. 
(A) The total number of compounds tested each day of the screening. (B) Z’ 
trend of plates tested in the HTS. Each test set represents plates from each 
day of screening. 
 
As seen in Figure 4.2, the control populations show a very good separation with 
each of them showing a bell-shaped normal distribution of responses. As 
discussed earlier the cut-off for marking the hits is calculated as: 
 
                         
 
The reasoning is that a response > 3SD is less likely to be a chance fluctuation 
from the population of inactive compounds. The hit cut-off was calculated to be 
24.23% response, resulting in 5331 robust actives i.e. a hit rate of 0.3 %. 
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Figure 4.2: Response in the primary HTS.  
(A) and (B) The x axes represent the normalised response and the y axes 
represent the number of rows, equal to the number of compounds showing that 
response. Marked in pink are the robust actives (9405). The control 
populations are shown in blue and green and the inactive population in grey. 
(A) The response of the entire collection in the HTS. A zoom of the area 
marked in dotted red rectangle is shown in (B) to show the distribution of 
robust actives. 
 
111 
 
As frequently observed in HTS, the plates showed a pattern (Figure 4.3), which is 
likely attributed to the dispensation technique used (Coma et al., 2009). The 
pattern was identified and corrected for as described in Section 2.3.3.3 and as 
shown in Figure 4.3. The pattern correction reduced the variance of response and 
thereby lowered the 3SD cut-off from 24.43 % to 19.15 %, yielding 8315 hits. 
Transverse cut-off correction (hit rate by position) was also applied (section 
2.3.3.3) and led to 5268 hits at a 3.5SD cut-off. There is a significant overlap in the 
lists of compounds selected after each of these corrections. Additionally, for the 
most potent compounds (> 50 % response), we looked for analogues, i.e. tanimoto 
similarity > 0.8, in the 2-3 SD region. A total of 397 analogues were found and 
were included in the final selection. Combined, a total of 9405 hits were selected, 
giving a hit rate of 0.56 %. The hits were next tested in duplicate at the same 
compound concentration of 10 µM to check for reproducibility of inhibition and to 
remove false positives. 
 
 
 
Figure 4.3: Identification and correction of patterns in the plates from the 
HTS.  
The left panel shows an average response at each position of all tested plates. 
The identified response pattern is shown in the centre panel, while the right 
panel shows the responses after pattern correction. For the purpose of 
visualisation of the pattern, a response of 17.69 % is marked in red, 1.6 % in 
grey and a response of -16 % is marked in blue. 
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Figure 4.4: Hit identification.  
 
4.2 Hit confirmation at single concentrations 
 
We selected 9405 compounds to be tested again in duplicate under the same 
conditions as the primary screen, i.e. a compound concentration of 10 µM, to 
confirm compound activity against TbrDUB1 and identify false positives. Of these, 
221 compounds could not be tested due to limited compound availability at the 
time of the confirmation screen, leaving 9184 compounds. However, these 221 
compounds were (later) incorporated in downstream dose response studies. None 
of the tested plates failed the quality control and the average Z’ value of each 
replicate set was 0.60 and 0.59 with a SD of 0.03 and 0.04, respectively. In 
contrast to the primary screen, no strong plate patterns were recognized in the 
confirmation screen. Hence, the response data did not require correction. The 3SD 
cut-off in each replicate was similar to that in the primary screen (19.15 %), 19.76 
% in one replicate and 20.15 % in the other. Robust activity was confirmed for a 
total of 2020 compounds (22 % of the primary hits), with 1325 compounds being 
active in both replicates. As seen in Figure 4.5(A), the correlation of responses 
between the replicates was excellent. The correlation between the primary HTS 
response and the replicates is shown in Figure 4.5(B). For the analogs of potent 
compounds rescued from the 2-3 SD region of response in primary HTS, the 
HTS- 1.7 million compounds tested
At 3x SD cut-off, compounds with 24.23% (average) response 
were marked as robust actives – 5331 hits 
1. After pattern correction, the variance reduced and hence 3 SD cut off was 
equivalent to 19.15% (average) response – 8315 hits
2. Transverse cut-off correction (hit rate by position) was also applied – 5268 
compounds were identified which were added to the list of 8315.
3. The 2-3 SD region was searched for analogues of the most potent compounds –
397 analogues which were included in the final selection
A total of 9405 compounds were progressed to 
single shot confirmation
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confirmation rate was surprisingly high (18.2 %), amounting to 71 compounds. 
Therefore, a good number of compounds were rescued through this strategy and 
could help to better understand the structure-activity relationship (SAR) around the 
most potent compounds. 
 
Figure 4.5: Hit confirmation studies.  
A) Correlation of responses between the replicates. B) Correlation of 
responses between the primary screen and confirmation screen replicates. A 
hit level of zero (grey) represents primary hits that were not confirmed in either 
replicate. A hit level of one (blue) describes primary hits that were confirmed in 
one of the two replicates, while hits in green (hit level = 2) were confirmed in 
both replicates. A total of 2020 primary hits (22 %) were confirmed. 
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4.3 Analysis of physicochemical properties of confirmed hits 
 
The importance of the physicochemical properties of compounds cannot be 
overstated. Several studies analysing approved oral small-molecule drugs or 
molecules in development, showed that the  likelihood of a compound to progress 
from early development to clinical trials increases when certain physicochemical 
properties are controlled (Lipinski et al., 1997, Lipinski, 2000, Lipinski et al., 2001, 
Leeson and Springthorpe, 2007, Gleeson, 2008, Hughes et al., 2008, Peters et al., 
2009, Gleeson et al., 2011, Luker et al., 2011, Waring et al., 2015). The links of 
physicochemical properties to absorption, distribution, metabolism and excretion 
(ADME) (Lipinski et al., 1997, Lipinski, 2000, Lipinski et al., 2001, Leeson and 
Springthorpe, 2007, Gleeson, 2008), promiscuity (Leeson and Springthorpe, 2007, 
Peters et al., 2009), in vivo toxicology (Hughes et al., 2008, Luker et al., 2011, 
Waring et al., 2015) and clinical safety (Waring et al., 2015) are well established. In 
1997, Lipinski et al. (Lipinski et al., 1997, Lipinski et al., 2001) established a rule of 
five by analysing a set of 2245 small molecules in phase II studies or beyond. The 
rule of five states that the likelihood of good permeation and absorption of a 
compound is higher when its  
a) molecular weight is < 500 Da,  
b) the calculated octanol-water partition coefficient (clogP) is < 5,  
c) the number of hydrogen bond acceptors is < 10 and  
d) the number of hydrogen bond donors is < 5.  
 
It is worth noting that this rule only applies to compounds that passively diffuse 
while compounds that are actively transported across membranes are excluded 
from this rule. In addition, the property forecast index (PFI), defined as clogDpH7.4 + 
number of aromatic rings, has been shown to be an effective indicator of 
compound solubility (Hill and Young, 2010, Young et al., 2011). Using a combined 
data set of 812 oral, small-molecule drug candidates nominated for development 
between 2000 and 2010 by Astra Zeneca, Eli Lilly, GlaxoSmithKline and Pfizer, it 
was observed that compounds failing in phase I due to clinical safety issues, have 
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a higher clogP than compounds that progressed to phase II (Waring et al., 2015). 
The same study also showed that zwitterionic compounds fare better compared to 
acidic, basic or neutral compounds in preclinical and clinical toxicology studies, but 
perform worse in pharmacokinetics studies in phase I (Waring et al., 2015). Using 
the above information as guideline, we analysed the physicochemical properties of 
the TbrDUB1 hits to identify compounds with the highest chances of progressing to 
the next phases. Hits with undesirable physicochemical properties were not 
discarded but were ‘red-flagged’. 
 
The distribution of several physicochemical properties of the confirmed 2020 hits is 
shown in Figure 4.6. The majority of TbrDUB1 hits have desirable drug-like 
physicochemical properties in conformation with the rule of five and have number 
of aromatic rings < 3 and PFI < 8. Looking at these distributions it is clear that the 
TbrDUB1 assay is not biased for any physicochemical property for the selection of 
hits. This also indicates that if some of our hits pass all the secondary filters 
described in the next chapter, there will be high chances of the selected hit being a 
good starting point for lead discovery and lead optimization studies. 
 
 
Figure 4.6: Physicochemical properties of confirmed hits. 
Most hits meet the criteria of drug-like physicochemical properties, i.e. 
molecular weight < 500 Da, clogP < 5, PFI < 8, no. of aromatic rings < 3, no. of 
hydrogen bond acceptors < 10, number of hydrogen bond donors < 5. In 
orange are the compounds that were active in one of the confirmation screen 
replicates (hit level = 1) and in brown are those that were active in both (hit 
level = 2). 
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4.4 Determination of potency of confirmed hits 
 
In order to determine the potency (IC50) of the confirmed hits, each compound was 
tested in duplicate at 11 concentrations in 1:3 serial dilutions, with a maximum 
concentration of 100 µM. In addition to the 2020 confirmed hits, 221 primary hits 
that could not be tested in the confirmation screen, were included to list of 
compounds for dose-response studies. However owing to compound availability 
issues, finally 2142 compounds were tested in dose response studies.  
 
The IC50 values were calculated by fitting the normalised data to a four parameter 
logistic fit equation defined as 
 
   
   
          
   
 
Where, x is the concentration of the test compound, y is the inhibition or activation 
(%), A is the maximum signal, D is the minimum signal (background), C is the IC50 
and B is the Hill slope. IC50 is the concentration of the compound at which it shows 
half (50%) of the maximum response observed. Expressing IC50 values in molar 
units, the pIC50 values are calculated as: 
           
 
    
  
 
As seen in Figure 4.7, the compounds’ pIC50 values show a very good 
reproducibility. As can be seen there is one compound with very good potency (7 < 
pIC50 ≤ 8) and 29 and 36 compounds respectively in the 2 replicates with pIC50 
between 6 and 7. In total 1412 and 1423 compounds respectively in the two 
replicates showed a dose response behaviour. 
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Figure 4.7: Correlation of pIC50 values between the two replicates.  
The pIC50 values of compounds were calculated from 11-point dose-response 
curves with a maximum compound concentration of 100 µM. The compounds 
are coloured by difference in pIC50 values in the 2 replicates- blue and green 
points show a difference of less than 0.5 in the pIC50 values, while red and 
black show a difference greater than 0.5. 
 
Table 4.1: The Z’ and distribution of potencies of TbrDUB1 hits in the two 
replicates. 
 
 Replicate 1 Replicate 2 
Robust mean Z’ 0.53 0.52 
Robust SD Z’ 0.04 0.03 
pIC50 ≤ 4 731 720 
4 < pIC50 ≤ 5 994 976 
5 < pIC50 ≤ 6 388 410 
6 < pIC50 ≤ 7 29 36 
7 < pIC50 ≤ 8 1 1 
Total 2143 2143 
 
 
Shown in Figure 4.8 are the dose response curves for all the compounds for each 
replicate. As discussed in section 2.3.3.2 based on the maximum response 
observed and the quality of fit the compounds were categorised as: inactive 
compounds, poorly active compounds, compounds that failed XC50 CL ratio, 
compounds with inappropriate fit, compounds with negative slope and lastly 
compounds that passed all fit parameters.  
118 
 
 
 
Figure 4.8 Dose response curves of the tested compounds.  
(A) and (B) show the dose response curves for the 2 replicates, respectively. 
The experimental and fitted data are plotted. Different panels show different 
ranges of the calculated pIC50 values. The compounds were categorised based 
on the maximum response observed and the quality of data fitting. These 
categories are coloured as indicated.  
 
In summary, we ran a successful HTS campaign and identified 2020 robustly 
active compounds, several of which showed high inhibition. We also determined 
the potencies of these confirmed hits that will be used for final selection of potent 
and selective hits. We also analysed these confirmed hits for their physicochemical 
properties and found them to be drug like which implies that we have good 
chances of identifying tractable hits. The next step is to characterise these hits to 
deprioritise compounds with undesirable mechanisms of action and low selectivity. 
  
 
 
 
Chapter 5 Hit characterisation  
 
 
Abstract  
In this chapter, we present results from different biochemical assays that aimed at 
filtering out compounds with undesirable redox-based mechanism of action (MOA) 
and those with non-selective activity against cysteine proteases. We further tested 
the TbrDUB1 hits against the parasite T. brucei to evaluate their whole-cell 
activity/effect on parasite growth and against T. brucei overexpressing TbrDUB1 to 
confirm on-target activity. Selected compounds were also tested against the 
related parasites Leishmania donovani and T. cruzi for cross-species activity, and 
in cytotoxicity studies against the mammalian cell line HepG2. A final selection of 
prioritised hits and their physicochemical properties is presented. 
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5.1 Secondary biochemical assays 
 
Compound interference is an unavoidable nuisance in most, if not all, HTS. 
Successful characterisation of hits from an HTS involves identifying what is 
undesirable and also what is of value. There are several modes of compound 
interference-both physical and chemical. Physical modes of interference could 
include fluorescence from the compound itself (autofluorescence) and compound 
aggregation. Autofluorescence is typically seen at the lower end of the visible 
spectrum. Since the fluorophore (5-TAMRA) in the Ub-FP substrate shows 
emission at a high wavelength (579 nm), we observed very few compounds with 
autofluorescence, which were removed. The strict quality control measures for the 
compound library maintenance and dispensation endeavour to remove compounds 
forming aggregates. 
 
 Chemical interference happens if a compound interacts with the buffer 
components and causes non-specific inhibition of the enzyme due to reactive 
products of such interactions.  Deubiquitinases are cysteine proteases. Cysteine-
containing enzymes are susceptible to DTT mediated oxidation of the cysteine by 
single electron donors (Lor et al., 2007) and oxidative inactivation by hydrogen 
peroxide that is generated by redox-active compounds in the presence of a strong 
reducing agent like DTT (Johnston et al., 2008, Mirkovic et al., 2011, Johnston, 
2011, Soares et al., 2010). Redox compounds are undesirable non-tractable hits 
because of known toxicity (Rana et al., 2013). In order to identify and remove such 
compounds from the TbrDUB1 hits, we tested them in eleven-point dose response 
(100 µM maximum conc., 1:3 serial dilution) in four complementing biochemical 
assays. Three of them were performed using HTS conditions, each with one of the 
following modifications: 
1) The assay buffer lacks DTT.  
2) The assay buffer additionally contains superoxide dismutase (SOD) and 
catalase to convert potentially formed superoxide radicals and hydrogen 
peroxide to water and molecular oxygen.  
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3) DTT in the assay buffer is replaced by the weaker reducing agent L-
cysteine. 
Compounds that remain active against TbrDUB1 in these assays are considered 
valid hits, while inactive ones are flagged as presumably redox-active compounds. 
In the fourth assay (Lor et al., 2007), the compounds are incubated with resazurin 
in the presence of DTT. Redox-active compounds catalyse the DTT mediated 
reduction of resazurin to the highly fluorescent resorufin and can be easily 
identified through measurement of fluorescence intensity. The compounds that 
show activity in this assay will be deemed undesirable and removed from the final 
selection of compounds. 
 
When working with targets from a pathogen, another important filter is activity 
against a human orthologue of the target, if known, or against a relevant class of 
human enzymes. TbrDUB1 belongs to the large family of cysteine proteases, 
which are named after the conserved cysteine residue in their active site. 
Compounds that are active against TbrDUB1 might be non-selective for TbrDUB1 
and also inhibit other cysteine proteases in the parasite and, more importantly, in 
the human host where they might lead to toxicity through various off-target effects. 
To exclude such compounds, we also tested the TbrDUB1 hits in 11-point dose-
response (100 µM maximum conc., 1:3 serial dilutions) against human Cathepsin 
B, a lysosomal cysteine protease. 
 
The results of these five assays are summarized in Table 5.1 and Figure 5.1. As 
expected, a large number of compounds showed high potencies in the resazurin to 
resorufin redox assay, highlighting the importance of this assay as a filter. Several 
compounds showed bell-shaped dose response curves in this assay. Thus, instead 
of pIC50, the maximum response > 30% in this assay is used as a cut-off for 
marking redox active compounds. Most compounds that were active against 
TbrDUB1 in the primary assay were inactive when DTT was replaced with the 
weaker reducing agent L-cysteine. 173 of the 2143 tested compounds showed a 
pIC50 > 4 in this assay, suggesting that most hits from the primary screen inhibit the 
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enzyme via an undesirable mechanism of action. A total of 1970 compounds were 
either inactive of failed to give a response > 30% at any concentration tested in the 
L-cys assay. Similar results were obtained from the assay with superoxide 
dismutase and catalase, confirming a significant number of non-specific 
compounds. As expected, the assay performance was poor in the absence of DTT 
due to a small assay window, which is attributed to the lower enzyme activity in a 
non-reducing environment. The results from this assay are not considered when 
finally selecting compounds, however this assay could again provide activity 
information for some compounds which will be useful for the chemists to make an 
informed decision when optimising the hits, at a later stage. Lastly, 82% (1785) of 
the tested compounds were inactive against human cathepsin B, indicating that 
most of the TbrDUB1 hits might have specific activity against DUBs. 
 
Together, the results demonstrate that a large number of hits show undesirable 
MOAs and could have liabilities due to their activity against a host cysteine 
protease. This highlights the importance of including secondary assays in the 
characterisation of identified hits.  
 
Table 5.1 The Z’ and distribution of potencies of TbrDUB1 hits in different 
secondary biochemical assays. 
 
Assay L-Cys Sod/Cat - DTT Redox hCTSB 
Robust Mean Z' 0.4 0.48 -0.21 0.62 0.75 
Robust SD Z' 0.04 0.02 0.12 0.04 0.06 
pIC50 ≤ 4 1970 2037 1274 899 1785 
4 < pIC50 ≤ 5 146 76 665 290 332 
5 < pIC50 ≤ 6 27 30 194 606 55 
6 < pIC50 ≤ 7 0 0 8 302 2 
7 < pIC50 ≤ 8 0 0 2 42 0 
8 < pIC50 0 0 0 3 0 
Total 2143 2143 2143 2142 2174 
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Figure 5.1: pIC50 values in secondary biochemical assays. 
 (A) Numbers of compounds showing pIC50 values in the ranges binned by a 
pIC50 difference of 1 in different secondary biochemical assays. (B) 
Comparison of observed pIC50 values from the different biochemical secondary 
assays to those from the primary (1ry) biochemical assay. Marked in green are 
the hit validation assays and in red the hit invalidation assays. 
 
 
We filtered the hits by overlaying the results of the primary and secondary assays 
(Figure 5.2). pIC50 values from the L-cysteine assay were used as indicator of 
compound activity with no undesirable mechanism of action. Compounds that were 
inactive against human cathepsin B (pIC50 ≤ 4) and those that showed a maximum 
response of less than 30 % in the resazurin redox assay were selected. The 
selectivity window (in pIC50) was defined as:  
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with the following tiers: 
SW ≥ 1: Most selective 
0.5 ≤ SW < 1: Selective 
0 < SW < 0.5: Least selective 
 
The analysis led to 20 most selective compounds, 23 selective compounds and 21 
least selective compounds. The highest observed selectivity window was a pIC50 
difference of 1.89.  
 
To summarise, starting from a library of ~1.7 million compounds, we identified 64 
TbrDUB1 hits which do not show redox MOA and do not show activity against a 
host cysteine protease. 
 
 
 
 
Figure 5.2: Hit selection.  
pIC50 values in the L-Cys assay and the selectivity windows of the selected 64 
TbrDUB1 hits.  
 
 
125 
 
5.2 Whole-cell assays 
 
5.2.1 Compound activity against wild-type versus DUB-overexpressing T. 
brucei 
 
We checked the cidal activity of TbrDUB1 hits against T. brucei and compared it to 
the activity against T. brucei cells overexpressing the TbrDUB1. The rationale 
(Figure 5.3) for this assay is that if the compound acts on-target and is cidal, 
overexpression of the target DUB should make the parasite less sensitive to the 
compound. This is measured as the shift in pIC50 values between wild-type and 
DUB overexpressing parasites. However, in case of redundancy amongst parasite 
DUBs or if the levels of overexpression are low, the shift in pIC50 is expected to be 
subtle. 
 
 
Figure 5.3: The principle of T. brucei whole cell DUB-overexpressor vs. 
wild-type assay. 
 
5.2.1.1 Demonstration of myc6 TbrDUB1 overexpression 
 
Mutant 2T1 Trypanosoma brucei brucei cell line derived from strain s427 were 
kindly provided by Dr. Boris Rodenko. The mutant contains the TbrDUB1 gene 
under the control of a tetracycline operator in the ribosomal RNA locus on 
chromosome 2a (Jones et al., 2014, Alsford and Horn, 2008). This allows 
tetracycline induced overexpression of the myc6TbrDUB1 gene product. As 
described in the section 2.3.10, overexpression of myc6TbrDUB1 was confirmed in 
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the parasite cells used for screening using SDS-PAGE and western blotting. The 
uninduced (tet-) cells do not show any expression of myc6TbrDUB1, while induced 
cells (tet+) show a band at the expected molecular weight when probed with anti-
myc tag antibodies indicating the expression of myc6TbrDUB1 (Figure 5.4). 
Furthermore the myc6TbrDUB1 band intensity is comparable when compared for 
equivalent cell lysate pre-screening and after another 24 hours- the duration of the 
screening. Using activity based protein profiling (ABPP) it has been shown that this 
mutant line shows 2-3 fold overexpression of TbrDUB1 (data not shown, oral 
communication from Dr. Boris Rodenko). 
 
 
 
Figure 5.4 Overexpression of myc6TbrDUB1 in the parasites.  
The band intensities in stain free image and also in the stain free channel in 
the second panel serve as loading controls. The positive control for the anti-
myc antibody is a commercial E. coli lysate containing a protein expressing the 
myc6-tag. Pre and post screening timepoints show similar myc6TbrDUB1 
(measured using Biorad Image Lab 5.1 software package).    
 
5.2.1.2 Screening 
 
We tested the effect of all ~2000 TbrDUB1 hits on the parasite using an ATP 
based viability assay described in (Sykes and Avery, 2009) and used as an 
Multichannel imageStain free image of the gel used for western Western with anti-myc antibody
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orthogonal assay in (Pena et al., 2015). In brief, the screening was performed in a 
1536-well plate at a final volume of 6 µL in the presence of 25 nL of compound in 
DMSO. Since the assay has a tolerance limit of 0.4% towards DMSO (determined 
previously) and since the highest available compound stock concentrations are 10 
mM, the highest compound concentration tested was 41.67 µM, followed by ten 1/3 
dilutions. In the case of overexpression of myc6 TbrDUB1, it was induced with 1 
µg/mL tetracycline (from a 1000x stock in 70% EtOH) at least 96 hours before 
screening. Cells were maintained in log-phase of growth without selection 
antibiotics for at least 24 h before exposing them to the compounds. 300 cells in 
6 µL growth medium were dispensed per well and after 24 h of incubation with 
compound, viable cells were quantified by measuring the ATP content in each well 
using Promega CellTitre-Glo luminescent cell viability assay reagent. The 
luminescence was measured using ViewLux microplate readers. The assay 
performed robustly with a Z’ of ~0.8 and was quite reproducible as seen by a good 
correlation of the pIC50 values. Owing to the absence of known specific TbrDUB1 
inhibitors, we tested the performance of the assay using 27 trypanocidal 
compounds (commercial and GSK compounds previously identified in a phenotypic 
screen) and the pan-DUB-specific inhibitor H1, which was confirmed to be active 
against TbrDUB1 (section 3.4.1). However, H1 will affect parasite viability by non-
selectively inhibiting several DUBs and thus we would not expect a pIC50 shift with 
H1. As can be seen in Figure 5.5, the correlation of tool compound performance in 
wild-type and DUB-overexpressing parasites is excellent. These trypanocidal 
compounds are expected to affect parasite viability in a DUB-independent fashion 
and thus not show a shift in the pIC50 values. Several of the trypanocidal 
compounds showed a slightly higher potency in DUB-overexpressing parasites, 
suggesting that overexpression of TbrDUB1 might impact parasite fitness. We thus 
believe that a small increase in the pIC50 value against wild type parasites could 
mean that the compound is on-target. H1 showed an average pIC50 of 4.9 and 5.2 
in the wild-type and DUB-overexpressing parasites, respectively. As expected, it 
does not show a pIC50 shift when comparing the two conditions. 
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Figure 5.5: Correlation of pIC50 values of trypanocidal compounds and H1 
in the whole-cell assay.  
Wild-type (uninduced) and DUB-overexpressing (induced) parasites were 
treated with trypanocidal compounds to evaluate the performance of the assay. 
The sizes of the points vary depending on the maximum response in the wild-
type parasites. The lines are drawn at y = x+0.5, x, x-0.5 and x-1 to see a pIC50 
shift, if any. 
 
 
 
Figure 5.6: Correlation of pIC50 values of TbrDUB1 hits in the whole-cell 
assay.  
All compounds were tested in the whole cell assay comparing the pIC50 values 
in wild type and parasites overexpressing the DUB. The data shown above are 
average of pIC50 values observed in 2 replicates. The colouring is according to 
the definitions in section 5.1 for most selective, selective and least or less 
selective compounds. The shape is defined by the pIC50 observed in the L-cys 
assay. The size is defined by the maximum response observed against the 
wild-type parasites.  
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Figure 5.7: Response of the 64 selected hits in the whole cell assay.  
The colouring is according to the definitions in section 5.1 for most selective, 
selective and less selective compounds. The shape is defined by the pIC50 
observed in the L-cys assay. The size is defined by the maximum response 
observed in the wild-type parasites.  
 
Shown in Figure 5.6 are the potencies of all TbrDUB1 hits against the wild-type 
and DUB-overexpressing parasite. pIC50 values of up to 6.2 were observed. In 
Figure 5.7 we show the 64 compounds that passed all the biochemical filters. The 
most potent compounds in the whole cell assay fail in some of the biochemical 
assays and hence did not get selected. The selected 64 compounds show a low, 
but decent at hit stage, potency. 
 
We failed to observe big shifts in pIC50 values from wild type to overexpressor. This 
could be due to a) low-level overexpression of TbrDUB1 (2-3 fold), insufficient to 
confer drug tolerance and cause a change in the pIC50 value, b) off-target activity 
or c) fitness loss, i.e. increased drug sensitivity, of TbrDUB1 overexpressing 
parasites which would lead to a reverse shift of pIC50 values, yielding a small net 
shift. Considering that we observed the trypanocidal compounds to show higher 
potencies against TbrDUB1-overexpressing parasites, the latter scenario seems 
plausible. Nevertheless, we have identified TbrDUB1 hits which show a cidal effect 
against T. brucei. 
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5.2.2 Cytotoxicity profiling using HepG2 cells 
 
To obtain information about possible acute in vitro cytotoxicity of the TbrDUB1 hits, 
we tested them on the human liver-derived HepG2 cell line in 11-point dose 
responses (100 µM max compound concentration; section 2.3.13). Compounds’ 
cytotoxicity is measured by intracellular ATP concentrations after 48 h incubation 
with compounds, using a luciferin/luciferase reaction. Mitochondrial function and 
cell redox state are both markers for cell health, and impairment of either result in a 
decrease in intracellular [ATP] (Crouch et al., 1993). Whether in vitro cytotoxicity 
translates to in vivo toxicity depends on a number of factors including therapeutic 
dose, free plasma concentration, metabolism, excretion etc. However, the 
compounds that are active in this assay can be flagged as undesirable, unless 
proven otherwise in in vivo studies. . As is seen in Figure 5.8, no compound has a 
pIC50 > 6 in the cytotoxicity assay and hence all hits qualify the absolute threshold 
for marking positives in this assay. Looking at relative cytotoxicity response, i.e. 
pIC50 values in the parasite versus HepG2 cells, several compounds, including 
some of the compounds in the ‘most-selective’ tier show up to a ~ 3-times lower 
IC50 (~ 0.5 log units higher pIC50) against the parasite. These compounds could be 
the promising hits to follow up with chemistry efforts to increase potency and 
improve selectivity. 
 
Figure 5.8: pIC50 values of the 64 selected compounds in the HepG2 
cytotoxicity assay. 
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5.2.3 L. donovani and T. cruzi whole-cell assays 
 
The orthologues of TbrDUB1 in the related Kinetoplastid parasites L. donovani and 
T. cruzi are highly similar in amino acid sequence, sharing 48 % and 38.6 % 
identity, respectively, with TbrDUB1 (Figure 3.4) It is therefore reasonable to 
assume that TbrDUB1 hits also inhibit the respective orthologues in L. donovani 
and T. cruzi. As described in the materials and methods both the whole cell assays 
have three readouts each: percentage of infected cells, ratio of parasites per host 
cell and percent response against the host cell. Thus this assay gives us response 
against the parasite and host cells which indicates cytotoxicity. These responses 
are normalised to the appropriate controls and used to calculate the pIC50. Of the 
64 prioritized compounds, 61 were available for testing them in dose response 
against L. donovani and T. cruzi. As shown in Figure 5.9, we see some potent 
compounds against both the parasite, but most of them also showed activity 
against host cells. Two compounds were selected that showed significantly higher 
pIC50 against the parasites compared to the host cell. Both compounds belong to 
the same cluster (cluster 24; Figure 5.12) and hence are structural analogues 
(Figure 5.23). Interestingly, they do not cluster with known DUB inhibitor 
(discussed later, Figure 5.12), suggesting that they are novel chemical entities.  
Furthermore, these compounds have passed a very thorough biochemical profiling 
and show no cytotoxicity against HepG2 cells, making them promising compounds 
for progression. 
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Figure 5.9 Response in L. donovani and T. cruzi whole cell assays.  
The TbrDUB1 hits were tested in whole cell assays and shown here are pIC50 
values in these assays compared to pIC50 in the primary biochemical assay. 
Since there were 2 outputs against the parasite in the whole cell assay, 
presented are (A) pIC50 values calculated using % infected cells as the output 
and (B) pIC50 values calculated using amastigotes per host cell. The two most 
promising compounds are circled. 
 
5.3 In-silico clustering of compounds 
 
In order to identify structural analogs amongst TbrDUB1 hits, we performed a 
complete-link hierarchical clustering of the 64 prioritized compounds, based on the 
tanimoto distance (Leach and Gillet, 2007). Studying the differences in the 
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potencies of structural analogs in different assays provides very valuable SAR 
information for the chemists to try to optimise the potency and selectivity of the 
compounds. For clustering, a digital fingerprint is generated for each compound 
based on its chemical structure and then a tanimoto score is obtained based on 
similarity of these digital fingerprints. Tanimoto score can range between 0 and 1, 
with 1 indicating highest similarity. For the clustering we defined a cut-off of 
tanimoto score > 0.55 for compounds to fall in the same cluster. As shown in 
Figure 5.10, we identified eleven clusters and 26 singletons. The largest family 
contains nine compounds, followed by a family of six and four compounds, 
respectively, and several families with two or three compounds each. It is 
interesting to note that within some families there are compounds with higher and 
lower selectivity and compounds from same cluster show different potencies in the 
T. brucei whole cell assay (Figure 5.11). This offers hints towards the SAR based 
on the functional groups these compounds contain. 
 
 
Figure 5.10: Complete-link hierarchical clustering of the 64 selected hits.  
X-axis (Clink) is the cluster in which the compounds fall and the y-axis 
(N_Clink) is the number of compounds per cluster. The colours are defined by 
the selectivity window cut-offs described above. 
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Figure 5.11: Compounds from same cluster show different but similar 
potencies. 
 
The next question we tried to answer was whether the discovered TbrDUB1 hits 
are new chemotypes from the GSK library or are they similar to known DUB 
inhibitors. For this, a clustering attempt was made with known inhibitors of DUBs 
and TbrDUB1 hits. The list of known DUB inhibitors that were used in this 
clustering is presented in Table 1.2. 
   
Only two of our hits clustered each with one of the known USP7 inhibitors: 
spongiacidin C (22) and HBX19818 (23). All the other TbrDUB1 hits clustered into 
different clusters or as singletons. The results are shown in Figure 5.12. Cluster 
numbers 15 and 16 represent the 2 hits that cluster with spongiacidin C and 
HBX19818 respectively. It can be concluded that most of the TbrDUB1 hits that we 
have discovered new families of compounds as Trypanosoma brucei 
deubiquitinase inhibitors. Whether these compounds are selective against 
TbrDUB1 compared to human DUBs still needs to be tested. 
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Figure 5.12: Clustering of 64 selected hits with known inhibitors of DUBs.  
Only 2 of our hits cluster with known inhibitors: spongiacidin C and HBX19818 
shown in clusters 15 and 16 respectively. Both of these are USP7 inhibitors. 
 
5.4 Physicochemical properties of the selected compounds 
 
The physicochemical properties of these compounds were checked to look for 
potential red flags due to undesirable properties. The physiochemical properties 
have been described and discussed in detail in the previous chapter.  The different 
physicochemical properties of the 24  TbrDUB1 hits out of 64 selected after 
biochemical assays (Figure 5.2)  can be seen in Figure 5.13 - Figure 5.18. These 
24 hits are chosen based on their pIC50 values and maximum response against 
wild-type parasites. The physicochemical properties presented are clogP, 
molecular weight, number of aromatic rings, number of hydrogen bond acceptors, 
number of hydrogen bond donors and property forecast index (PFI). Overall, the 
TbrDUB1 hits have desirable physicochemical properties and, if progressed, offer a 
chance of chemistry efforts for further optimisations. Additionally, from the 
distribution of the compounds we can conclude that our assay is not biased for any 
particular physicochemical property. 
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Figure 5.13: clogP of selected compounds 
 
 
Figure 5.14: Molecular weight of selected compounds 
 
 
Figure 5.15: Number of aromatic rings in selected compounds 
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Figure 5.16: Number of hydrogen bond acceptors in selected compounds 
 
 
Figure 5.17: Number of hydrogen bond donors in selected compounds  
 
 
Figure 5.18: PFI (property forecast index) of the selected compounds 
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We also retrieved information about the promiscuity of TbrDUB1 hits from historical 
data from the HTS carried out at GSK in the past. Inhibition Frequency Index (IFI) 
is defined as the % of assays in which a compound showed > 50 % inhibition in 
HTS screening run at 10 µM. 
          
Where 
A= Number of % inhibition instances recorded in unique non kinase Assays  
B= Number of times the Median value of % inhibition > 50 %  
 
IFI values below 5% are considered “clean”, between 5 and 10% “suspicious”, and 
> 10% are “potential nuisance”. It is important to note that the statistical 
significance of IFI values should be judged by the number of tests recorded per 
compound. As a rule of thumb, at least 50 tests should be available to obtain an 
accurate measure of IFI, though extreme values with lower counts can be 
meaningful as well. The IFI values for TbrDUB1 compounds are shown in Figure 
5.19. The number of assays used to calculate the IFI values are shown in Figure 
5.20. TbrDUB1 hits have small IFI values which increases the confidence that they 
could be on target. 
 
 
Figure 5.19: IFI (inhibition frequency index) of the selected compounds. 
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Figure 5.20: Assay count used to calculate the IFI for the selected 
compounds.  
 
Lastly, we compared the distribution of physicochemical properties of 64 TbrDUB1 
hits to those of 771 marketed drugs. As can be seen in Figure 5.21, the distribution 
of physicochemical properties of TbrDUB1 hits overlaps with the distribution of 
marketed drugs which gives confidence that the selected 64 TbrDUB1 hits are 
indeed drug-like.  
 
 
Figure 5.21: Comparison of physicochemical properties of TbrDUB1 hits 
with those of marketed drugs.  
Marketed drugs (grey) and TbrDUB1 selected hits (orange) show a similar 
distribution of physicochemical properties. TbrDUB1 hits are thus good starting 
points for medicinal chemistry efforts.  
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5.5 Selection of high-priority hits 
 
Keeping in mind all the biochemical assays, the T. brucei whole assay and the 
cytotoxicity assay, a selection of the high priority hits was made. These hits stand 
the highest chance of success if followed up with efforts to increase potency and 
selectivity and obtain a good dose, metabolism and pharmacokinetics (DMPK) 
profile. 
 
The criteria used for selection of high priority hits from the 64 that have already 
been selected (Figure 5.2) are: 
 0.4 ≤ (pIC50 Uninduced-pIC50 cytotox) ≤ 1.46 
 Tier: Most selective and selective 
 
A pIC50 difference of 0.4 represents approximately 2.5 times difference in the IC50 
value. Using these criteria we were able to select 14 compounds that have a range 
of pIC50 values against the wild-type T. brucei from 4.41 to 5.56. It is interesting to 
note that three compounds each from cluster numbers 2, 4 and 6 (as shown in 
Figure 5.10) are in the final selection which means these clusters contain valuable 
SAR information for follow-up studies. Presented in Figure 5.22 are the structures 
of the compounds that we consider high priority. 
 
 
Figure 5.22: Structures of the high priority compounds. 
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Lastly, we also selected two most promising TbrDUB1 hits that elicit a response 
against the three parasites tested viz. T. brucei, T. cruzi and L. donovani and show 
little or no response against the host cells. They have passed a very thorough 
biochemical profiling and don’t show cytotoxicity against HepG2 cells. The pIC50 
values of these compounds are shown in Table 5.2 and the structures of these 
compounds are shown in Figure 5.23. These compounds have  IC50 values of 3.98 
and 1.99 µM, respectively against L. donovani and 15 and 10.4 µM, respectively 
against T. cruzi. Both of these compounds are structural analogs. They cluster 
together in cluster number 24 (Figure 5.12) and do not cluster with any of the 
known DUB inhibitors. They are thiophene phenyl derivatives. 
 
In summary, after a set of five secondary biochemical assays and T. brucei whole 
cell assays, we identified fourteen high-priority compounds. Furthermore, after also 
including the results against whole cell L. donovani and T. cruzi, we identified two 
most promising hits that show activity against all three parasites.  
 
 
 
Figure 5.23: Structures of the highest priority TbrDUB1 hits.  
These compounds show cidal activity against all the three parasites tested and 
no cytotoxicity. 
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Table 5.2 Potencies of the two most promising compounds.  
pIC50 values of the two most promising compounds in different assays- primary 
biochemical assay, wild type (WT) and DUB-overexpressing T. brucei, T. cruzi, 
L. donovani and HepG2 cytotoxicity assay. For T. cruzi and L. donovani 3 pIC50 
values are reported calculated respectively from the 3 outcomes as response: 
% infected cells, amastigotes per host cell and response against host cell.  
 
Compound 
Number  
Biochemical 
assay  
T. 
brucei 
WT  
T. brucei DUB 
overexpressor  
T. cruzi (%inf / 
Am per cell / 
host cell)  
L. donovani (%inf / 
Am per cell / host 
cell)  
Cytotox 
assay  
58  5.14  5.06  4.97  4.8/4.4/4.3  5.4/5/4.3  4.7  
59  5.19  5.18  5.15  4.98/4.74/4.3  5.7/4.6/4.3  4.23  
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Supplementary data 
 
For the selected high-priority and most promising compounds (section 5.5), presented 
here are the structures, pIC50 values and physicochemical properties. 
 
Legend for the following tables: tier M: most selective; tier S: selective; CLink: cluster 
number; N_Ar_Rings: no. of aromatic rings; N_Chiral_Atoms/Bonds: no. of chiral 
atoms/bonds; clogP: calculated logP; cmr: calculated molar refractivity; N_Acceptors and 
N_Donors: no. of hydrogen bond acceptors and donors; N_Heavy_Atoms: no. of heavy 
atoms; N_Neg_Charge and N_Pos_Charge: no. of negative and positive charge; 
N_Rot_Bonds: no. of rotatable bonds; CNS_Penetration: Score of chances of penetrating 
the CNS; PFI: property forecast index; Assay_count: no of assays used to calculate IFI 
which is the inhibition frequency index. 
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Compound number Structure 
58 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
4.975 5.14 5.4 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.06 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.14 4.97 5.06 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4.705 0.355 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
9 3 0 
clogP cmr Flexibility_Index 
1.714 9.302 11 
N_Acceptors N_Donors N_Heavy_Atoms 
4 1 24 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
359.42 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
3 83.13 
 
PFI Assay_count IFI_50 
6.73 144 0.69 
Chemotype 
thiophene phenyl derivative 
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Compound number Structure 
59 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.24 5.19 5.62 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.36 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.19 5.15 5.175 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4.23 0.945 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
9 3 0 
clogP cmr Flexibility_Index 
2.064 8.767 11 
N_Acceptors N_Donors N_Heavy_Atoms 
4 0 23 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
347.41 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
3 76.3 
 
PFI Assay_count IFI_50 
7.87 92 1.09 
Chemotype 
thiophene phenyl derivative 
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Compound number Structure 
60 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.5 5.96 3.5 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.71 4.44 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.52 4.975 4.96 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4.065 0.895 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
4 2 1 
clogP cmr Flexibility_Index 
4.465 8.851 8 
N_Acceptors N_Donors N_Heavy_Atoms 
1 1 21 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
300.42 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
2 32.34 High 
PFI Assay_count IFI_50 
7.6 187 5.35 
Chemotype 
thiophene amide phenyl derivative 
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Compound number Structure 
61 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.435 5.75 5.46 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.96 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.75 4.38 4.59 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.59 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
6 2 0 
clogP cmr Flexibility_Index 
2.138 7.565 15 
N_Acceptors N_Donors N_Heavy_Atoms 
2 2 19 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
299.16 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
3 58.95 High 
PFI Assay_count IFI_50 
5.41 158 1.27 
Chemotypes 
urea phenyl derivative 
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Compound number Structure 
62 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
4.67 4.87 5.2 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
4.98 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
0.87 4.38 4.7 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.7 S 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
6 2 1 
clogP cmr Flexibility_Index 
3.346 8.493 13 
N_Acceptors N_Donors N_Heavy_Atoms 
2 2 21 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
327.21 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
3 58.95 
 
PFI Assay_count IFI_50 
6.74 164 1.83 
Chemotypes 
urea phenyl derivative 
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Compound number Structure 
63 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.795 5.56 3.5 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.69 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.56 4.5 4.56 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.56 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
2 2 1 
clogP cmr Flexibility_Index 
3.089 11.711 19 
N_Acceptors N_Donors N_Heavy_Atoms 
5 0 29 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
435.56 1 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
6 95.91 
 
PFI Assay_count IFI_50 
7.32 154 1.95 
Chemotypes 
sulfonamide phenyl derivative 
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Compound number Structure 
64 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
4.585 4.93 5.17 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
4.57 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
0.93 5.59 5.46 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 1.46 S 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
14 4 0 
clogP cmr Flexibility_Index 
4.477 13.332 15 
N_Acceptors N_Donors N_Heavy_Atoms 
4 1 34 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
474.58 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
6 84.3 
 
PFI Assay_count IFI_50 
9.71 163 1.23 
Chemotypes 
benzimidazole amide phenyl derivative 
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Compound number Structure 
65 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.41 5.82 5.37 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.48 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.82 4.38 4.64 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.64 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
6 2 1 
clogP cmr Flexibility_Index 
2.447 8.029 14 
N_Acceptors N_Donors N_Heavy_Atoms 
2 2 20 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
313.18 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
3 58.95 
 
PFI Assay_count IFI_50 
6 148 0.68 
Chemotypes 
urea phenyl derivative 
 
  
152 
 
 
Compound number Structure 
66 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.51 5.68 5.92 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.53 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.68 4.38 4.56 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.56 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
1 2 0 
clogP cmr Flexibility_Index 
2.949 8.902 17 
N_Acceptors N_Donors N_Heavy_Atoms 
2 2 22 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
300.4 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
4 58.95 
 
PFI Assay_count IFI_50 
6.15 139 0.72 
Chemotypes 
urea phenyl derivative 
 
  
153 
 
 
Compound number Structure 
67 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
4.365 4.76 4.89 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
4.39 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
0.76 5.435 5.27 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4.725385 0.544615 S 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
24 4 0 
clogP cmr Flexibility_Index 
4.724 12.621 11 
N_Acceptors N_Donors N_Heavy_Atoms 
6 0 33 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
459.52 1 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
4 100.46 Low 
PFI Assay_count IFI_50 
7.33 119 13.45 
Chemotypes 
pyrimidyl carboxylate sulfonamide derivative 
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Compound number Structure 
68 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.115 5.32 5.63 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.11 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.32 4.38 4.525 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.525 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
29 2 0 
clogP cmr Flexibility_Index 
1.545 7.874 17 
N_Acceptors N_Donors N_Heavy_Atoms 
2 1 21 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
286.33 0 1 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
4 71.26 
 
PFI Assay_count IFI_50 
5.83 91 1.1 
Chemotypes 
pyridyl isoxazole amide derivative 
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Compound number Structure 
69 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
4.56 5.18 5.3 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
4.1 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.18 4.38 4.41 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.41 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
4 2 1 
clogP cmr Flexibility_Index 
4.376 13.042 16 
N_Acceptors N_Donors N_Heavy_Atoms 
4 1 33 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
471.61 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
6 78.95 
 
PFI Assay_count IFI_50 
7.58 217 0.46 
Chemotypes 
morpholino amide phenyl derivative 
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Compound number Structure 
70 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.375 5.43 5.35 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.37 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.43 4.38 4.49 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.49 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
4 2 1 
clogP cmr Flexibility_Index 
4.506 10.276 14 
N_Acceptors N_Donors N_Heavy_Atoms 
1 1 26 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
354.44 0 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
4 50.8 
 
PFI Assay_count IFI_50 
7.21 203 3.94 
Chemotypes 
amide ether phenyl derivative 
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Compound number Structure 
71 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
5.55 5.34 6.09 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.45 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.34 4.56 4.525 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.525 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
2 2 1 
clogP cmr Flexibility_Index 
2.479 11.864 18 
N_Acceptors N_Donors N_Heavy_Atoms 
5 0 30 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
451.56 1 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
6 105.14 Low 
PFI Assay_count IFI_50 
6.76 205 0.98 
Chemotypes 
sulfonamide ether phenyl derivative 
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Compound number Structure 
72 
 
Avg 1ry pIC50 pIC50 LCys pIC50 Sans DTT 
4.745 5.89 3.5 
pIC50 SOD/Cat pIC50 hCathepsin B pIC50 REDOX assay 
5.73 4 4 
Selectivity diff. Average Induced pIC50 Average Uninduced pIC50 
1.89 4.575 4.51 
Avg. pIC50 cytotox pIC50 diff. uninduced and cytotox Tier 
4 0.51 M 
CLink N_Ar_Rings N_Chiral_Atoms/Bonds 
2 2 1 
clogP cmr Flexibility_Index 
3.588 12.174 18 
N_Acceptors N_Donors N_Heavy_Atoms 
5 0 30 
Molecular_Weight N_Neg_Charge N_Pos_Charge 
449.59 1 0 
N_Rot_Bonds Total_Polar_Surface_Area CNS_Penetration 
6 95.91 Low 
PFI Assay_count IFI_50 
7.63 197 1.52 
Chemotypes 
sulfonamide phenyl derivative 
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Human diseases caused by Kinetoplastids have been neglected for several 
decades and hence the available treatments against HAT, Chagas disease and 
Leishmaniasis are obsolete. Serious efforts are needed for the discovery of novel 
treatments against these diseases. For the discovery of novel small treatments, 
both target based approach and phenotypic screening are very well validated 
approaches, each with its own advantages (Swinney and Anthony, 2011, Eder et 
al., 2014). Both of these approaches are being pursued at GSK for drug discovery 
efforts against Kinetoplastids. Phenotypic screening of the GSK compound 
collection led to identification of compounds that act against these three parasites 
(Pena et al., 2015). These compounds are available as an open resource for labs 
all over the world. Efforts are on for target deconvolution for these compounds. As 
a parallel effort, target based approaches are being used for the identification of 
novel and tractable hits. Target based approaches have an advantage over the 
phenotypic screening for intracellular targets and for intracellular parasites. 
Biochemical assays can provide diverse chemical starting points against a target. 
This can be followed with better informed follow-up chemistry efforts for lead 
generation. In this thesis we follow a target based approach focussed on an 
essential deubiquitinase in T. brucei. 
 
Ubiquitin was first discovered in 1975, much after most of the available treatments 
against these diseases were discovered. Ubiquitin biology has been mostly 
unveiled in the last two decades. Even though the field has shown a huge potential 
for discovery of novel therapeutic target, still not many compounds are available to 
inhibit the activity of various components of the ubiquitin pathway. The work in this 
thesis is an attempt to bring the ubiquitin drug discovery and Kinetoplastid drug 
discovery together. Deubiquitinases or ubiquitin specific proteases catalyse the 
removal of ubiquitin from the target proteins. Proteases, in general, have been 
highly researched and pursued as successful therapeutic targets. It is estimated 
that 5-10% of all pharmaceutical targets being pursued are proteases (Drag and 
Salvesen, 2010). With at least 30 marketed drugs targeting proteases against 
various diseases like hypertension, myocardial infarction, AIDS, respiratory 
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diseases and cancer, to count a few, proteases have emerged as the most 
prominent target family (Drag and Salvesen, 2010, Imming et al., 2006, Turk, 
2006). DUBs form one of the largest classes of proteases. DUBs are genetically 
and chemically validated targets in several therapeutic areas and even though it is 
difficult to achieve specificity, they have proven to be tractable targets. The work 
presented in this thesis is based on the initial discovery of essential 
deubiquitinases in T. brucei by Dr. Boris Rodenko et. al. Their work established 
deubiquitinases as genetically validated targets in T. brucei by RNAi screening. 
They also showed that inhibition of DUBs by pan-DUB inhibitors in T. brucei is 
cidal. 
 
We started with the aim of identifying trypanocidal inhibitors of TbrDUB1 and 
checking cross-species activity of these small molecules. For this we chose to 
perform a high throughput screening using a deubiquitinase biochemical assay and 
~1.7 million compounds from the GSK collection. The chances of discovering 
tractable hits from a HTS campaign increase with the size and quality of the library 
screened. HTS is thus a good example of chance discovery as opposed to 
knowledge based drug design. However, HTS has proven to be a successful 
approach for identification of small molecule inhibitors, with several marketed drugs 
having their origins from target based screening efforts (Macarron et al., 2011, 
Swinney and Anthony, 2011).  
 
The first phase of the work involved reagent generation and assay development. 
We expressed and purified active recombinant TbrDUB1 by expressing it in insect 
cells (Sf9). Insect cells were chosen as an expression system because TbrDUB1 
was insoluble in E. coli and it is likely that some post-translational modifications in 
a eukaryotic expression system improve its solubility. We were then able to set up 
a robust assay for the high throughput screening as shown in Figure 3.12 to 
Figure 3.15 and Table 3.1. The assay uses a substrate that has an isopeptide 
linkage, the biologically relevant substrate for the DUBs. When the performance of 
the assay was tested with 3 replicates of the validation set, a hit rate of 0.26% was 
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observed with a predicted confirmation rate of 69%. This meant that the HTS would 
give us around 3000 confirmed hits. A hit rate of 0.26% could be considered low 
because in some screens the hit rate is typically around 1%. However, this 
expected hit rate is very similar to a hit rate of 0.2% seen in USP7 screening using 
a fluorometric assay (Colland et al., 2009). 
 
 
 
Figure 6.1: The project plan.  
The plan of the work carried out and presented in this thesis. Starting from 
around 1.7 million compounds we have been able to prioritise 15 compounds 
(14 from one selection and 2 from another, 1 compound overlaps in these two). 
 
 
The HTS itself was set up to run in a semi-automated manner. The test compound 
dispensation in 1536-well plates was performed by acoustic transfer using Echo 
liquid handling system. The plate handling was done by Agilent direct drive robot 
and liquid dispensation using Thermo Multidrop® Combi, both controlled by Agilent 
VWorks automation software. For the screening, the maximum achieved 
throughput was of around 250,000 compounds on one day. The assay performed 
robustly for the HTS, with only 0.56% plates failing. The HTS yielded 5331 hits, 
Full diversity HTS
enzymatic activity ~1.7 million (n=1)
Hits confirmation
~9k (n=2)
Full curve analysis
~2K (n=2)
11-point serial dilutions of 
cmpds (down from 100uM) 
Reagents generation
Assay development
Secondary assays (~2K, full curve, n=1)
-1ry in absence of DTT
-1ry in presence of SOD/Cat
- 1ry in presence of L-Cys
-Resazurin to resorufin
-Human Cathepsin B
Phenotypic screen 
(pIC50 shift)
~2K
HepG2 cytotoxicity 
studies (61, FC)
64
Final selection of 14 
compounds
T. cruzi and L. 
donovani whole cell 
assay (61, FC)
Final selection of 2 
compounds
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which calculates to a hit rate of 0.3%. The observed cut-off at 3X SD was 24.23% 
inhibition at the tested concentration of 10 µM. To select compounds for 
confirmation studies, the patterns were corrected and weak analogs of potent 
inhibitors were also included and a total of 9405 hits were progressed to hit 
confirmation studies as shown in Figure 4.4. Of these, 2020 hits were confirmed 
as robust actives. To determine the potency and efficacy of these compounds, 
dose response studies were carried out and potency was determined by 
calculating the pIC50 values. These hits showed pIC50 values ranging from 4 to 
approximately 8.  
 
It is very important to remove compounds that act via undesirable molecular 
mechanisms of action and also compounds that could have potential liabilities 
because of their activity on host proteins. As discussed earlier, HTS is serendipity 
based drug discovery. Therefore, it is desirable to maximise the chances of hit 
identification in the primary HTS. The undesirable hits can be easily filtered using 
secondary assays; however in this process valuable SAR information is generated 
that could be very useful for the chemists when working on optimising the 
physicochemical properties of the hits. Using L-cysteine as the reducing agent in 
the primary assay would have significantly reduced the hit rates. Thus, we decided 
to use it as a secondary assay along with other assays to filter out or flag the 
undesirable compounds. In one of the assays we replaced the reducing agent from 
DTT to L-cys. In another assay we removed the reducing agent from the buffer. In 
a third assay we added superoxide dismutase and catalase to the assay buffer to 
remove superoxides and peroxide. In the fourth assay we profiled compounds for 
their redox potential by testing their ability to reduce resazurin to resorufin in the 
presence of DTT. And lastly, we tested the compounds for their activity against 
human cathepsin B. 64 compounds were selected at this stage after profiling in 
these five secondary assays. Based on their selectivity against human cathepsin B, 
we classified the 64 TbrDUB1 hits as- 20 most selective compounds, 23 selective 
compounds and 21 least selective compounds. A complete link hierarchical 
clustering of the 64 identified TbrDUB1 hits and 57 known DUB inhibitors, 
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presented in Table 1.2, was performed. Out of the 64 TbrDUB1 hits only 2 
clustered with known inhibitors of USP7- namely spongiacidin C (22) and 
HBX19818 (23). Neither of these 2 hits made it to our list of finally selected hits. 
HBX19818 has been shown to irreversibly inhibit USP7 by covalently binding 
Cys223 with an IC50 of 28.1 µM (Reverdy et al., 2012). The remaining 62 TbrDUB1 
clustered separately, in clusters or as singletons, indicating that these are novel 
DUB inhibitors.  
 
All the confirmed hits from the primary assay were also tested for their potency 
against T. brucei and we measured the change in this potency when the TbrDUB1 
was overexpressed. This is a powerful technique frequently referred to as “target-
biased phenotypic assay”. A mutant T. brucei cell line was used that allowed 
inducible TbrDUB1 overexpression. The 64 hits selected after biochemical profiling 
showed a pIC50 range of between 5.5 and 4.3 i.e. an IC50 range of 3.16 to 50 µM. 
However, we could not detect highly significant shifts in the pIC50 values of 
TbrDUB1 hits in wild type vs. overexpressor comparison. This could largely be 
attributed to low expression levels of the TbrDUB1 (2-3 fold overexpression). 
Additionally, as presented in Figure 5.5, the known trypanocidal compounds show 
a trend of higher potencies against the overexpressor, indicating that DUB 
overexpression could have a negative impact on the parasite’s “fitness”. Hence 
even a small decrease in pIC50 of TbrDUB1 inhibitors against the overexpressor 
could be significant. This leads us to ask the question that if a compound, having 
survived a thorough biochemical profiling, is not showing a shift in pIC50 when the 
target is overexpressed, then should it be considered on-target or not? This can be 
answered, in part, by using biophysical techniques such as affinity selection mass 
spectrometry and surface plasma resonance to demonstrate the binding of the 
compounds to the target protein. Activity based protein profiling can also be done 
with these hits to demonstrate on-target activity. Also, even though the pIC50 value 
is the same, maybe the compounds could show a different rate of kill of the 
parasite when the target is overexpressed.  
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The compounds selected after biochemical profiling were passed to cytotoxicity 
studies in HepG2 cells. We were able to identify 14 small molecules that were 
either not cytotoxic or had at least 2.5 times higher IC50 values against the T. 
brucei compared to HepG2 cells. 
 
Lastly, we also tested the selected 64 hits against T. cruzi and Leishmania 
donovani in whole cell assays to test for cross-species activity of the TbrDUB1 
inhibitors. We were able to identify 2 compounds that had potencies in the range of 
2 - 15 µM against T. cruzi and L. donovani, while being inactive against the host 
cells. These compounds are thiophene phenyl derivatives. Katsuno et al. (Katsuno 
et al., 2015) describe the hit selection criteria for visceral leishmaniasis and 
Chagas disease that has been agreed by various international agencies involved in 
drug development against neglected diseases. Both compound 58 and 59 conform 
to the hit selection criteria for visceral leishmaniasis (IC50 3.98 and 1.99 µM 
respectively). Their potencies against T. cruzi are 15 and 10.4 µM respectively. For 
compound 59 this is very close to the described cut-off – 10.4 µM vs. desired 10 
µM. Since these compounds act on all three parasites, they could hold a great 
value in follow-up efforts. Even though it might prove challenging, they present a 
good chance of developing one pill that treats three diseases. 
 
Even though the remaining TbrDUB1 hits have been put in lower priority groups, 
these hits still hold a lot of value. Efforts on improving their membrane permeability, 
for example, could lead to a better response in the whole cell assays. The selected 
high priority hits can go through a hit to lead campaign wherein medicinal chemists 
attempt to optimise the potency, permeability, solubility and selectivity of these hits 
to obtain compounds that have the chances of showing optimum pharmacokinetics 
(PK) and pharmacodynamics (PD). These hits and the resulting lead compounds 
could be tested in in vivo models to study the PK and PD. The mechanism of 
inhibition or action of these compounds also is still to be determined. A co-crystal 
structure of the TbrDUB1 with its inhibitors could help identify the binding sites. 
Also, it will be very valuable to screen the TbrDUB1 hits against a panel of human 
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DUBs. Such a screen will help us characterise the inhibitors for their selectivity. 
One possible outcome of this screen could also be activity against a validated 
target human DUB with implications in other therapeutic areas like oncology. 
Furthermore, since our target are diseases caused by Kinetoplastids, for which the 
existing treatments are old and have serious side effects, the therapeutic index of 
the compounds should be carefully taken into account before de-prioritising them 
for the fear of potential liabilities in case of any activity against human 
deubiquitinases. A very interesting line of follow up research could be to identify 
the effect of these compounds on the ubiquitome of the parasites. This could help 
us identify downstream targets of the TbrDUB1 and give hints towards the 
biological role and the targets of the TbrDUB1 which still need to de determined. 
Efforts are on for the genetic validation of Leishmania and T. cruzi DUB as a target, 
even though our work provides hints towards that via chemical validation given that 
the compounds are on-target in these parasites. In conclusion, the work presented 
in this thesis paves a very promising way forward for drug discovery efforts against 
the Kinetoplastids. 
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As a result of the work presented in this thesis we can conclude that -   
 We identified 64 TbrDUB1 small molecule inhibitors after biochemical 
screening and triaging. Only two TbrDUB1 hits cluster with known inhibitors 
of human USP7 while the remaining 62 cluster separately. Thus, we have 
identified novel inhibitors against deubiquitinases that could have 
applications against Kinetoplastids and could also hold potential against 
other therapeutic areas like oncology where DUBs play the roles of key 
regulators of cellular processes. 
 Out of the 64 TbrDUB1 hits we identified fourteen TbrDUB1 that do not act 
via redox mechanisms, show specificity when compared to activity a human 
cysteine protease and are cidal against T. brucei. Additionally, our work 
further chemically validates TbrDUB1 as a target in T. brucei. 
 Out of the 64 TbrDUB1 hits we identified two small molecule TbrDUB1 
inhibitors that are cidal against the three Kinetoplastid parasites – T. brucei, 
T. cruzi and L. donovani. These small molecules provide starting points for 
efforts to develop treatments against HAT, Chagas disease and 
leishmaniasis. This also indicates that the orthologues of TbrDUB1 in T. 
cruzi and L. donovani could be potential targets for therapeutic intervention. 
 All identified TbrDUB1 hits have drug-like physicochemical properties and 
are not promiscuous enzyme inhibitors. 
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De los resultados obtenidos en este trabajo de tesis se derivan las siguientes 
conclusiones:   
 Hemos identificado 64 moléculas pequeña que inhiben la TbrDUB1. Solo 
dos de los compuestos seleccionados para TbrDUB1 son análogos de 
inhibidores conocidos de una desubiquitinasa humana (USP7) mientras que 
los restantes 62 son estructuras novedosas. De esta forma, hemos 
identificado inhibidores novedosos de desubiquitinasas que podrían tener 
aplicación contra parásitos kinetoplástidos y podrían presentar también 
potencial en otras áreas terapéuticas como la oncología, donde las 
desubiquitinasas juegan importantes papeles como reguladores clave de 
procesos celulares.  
 De estos 64 moléculas, hemos identificado 14 moléculas que inhiben la 
TbrDUB1, no lo hacen mediante un mecanismo redox, muestran 
especificidad respecto a una cisteín-proteasa humana y son capaces de 
matar a T. brucei. Adicionalmente, nuestro trabajo avanza en la validación 
química de la TbrDUB1 como diana farmacológica en T. brucei. 
 De estos 64 moléculas, hemos identificado 2 inhibidores de la TbrDUB1 de 
molécula pequeña que matan a los tres parásitos kinetoplástidos de interés 
– T. brucei,  T. cruzi y L. donovani. Estas moléculas pequeñas representan 
puntos de partida para esfuerzos de desarrollo de nuevos tratamientos para 
la enfermedad del sueño, el mal de Chagas y la leishmaniasis. Este hecho 
sugiere además la presencia de ortólogos de TbrDUB1 en T. cruzi y L. 
donovani como dianas potenciales para la intervención terapéutica. 
 Todas las moléculas seleccionadas para TbrDUB1 poseen propiedades 
físico-químicas atractivas desde el punto de vista farmacológico y no son 
inhibidores enzimáticos promiscuos. 
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